US Pat. No. 10,362,815

ANTI-GRIP KIMONO

Lime Enterprises Limited,...

1. A reinforced martial arts kimono containing anti-grip reinforced panels which pop-off or release from the grip of an opponent grabbing the reinforced martial arts kimono, the reinforced martial arts kimono comprising:a kimono jacket that is formed from a first material;
the kimono jacket including right sleeve and right body portions;
the kimono further including left sleeve and left body portions and a collar;
the collar extending upwardly from upper ends of each of the left and right sleeves;
the right body portion includes an inner flap and the left body portion includes an outer flap;
each body portion includes a lapel which is contiguous with the collar;
the lapels extending downwardly from the collar toward the bottom of the kimono jacket;
wherein the lapel and inner flap of the right body portion extends under the lapel of the left body portion toward a left side of the wearer of the kimono jacket and the lapel and the outer flap of the left body portion extends over the inner flap of the right body portion and extends toward a right side of the wearer of the kimono jacket;
and the lapels and body portions are configured to be kept in place by a martial arts belt;
at least two anti-grip reinforcement panels affixed to an inside surface of the interior of the reinforced martial arts kimono;
the at least two reinforcement panels being located on the inside of the kimono form annular-shaped anti-grip reinforcement panels and the at least two reinforced panels are affixed to the inside of the sleeves of the reinforced anti-grip martial arts kimono jacket, adjacent to the cuffs of the each of the sleeves;
the at least two anti-grip reinforcement panels being of a second material which is different material than the first material forming the kimono jacket, the two reinforcement panels providing a sufficient popping-off tactile sensation or release of grip of an opponent grabbing the reinforced anti-grip martial arts kimono during the practice of martial arts;
and
wherein the second material adjacent to the cuff of each of the left and right sleeves extends from the cuff upwardly toward the collar of the anti-grip martial arts kimono jacket.

US Pat. No. 10,362,814

PANTS CONFIGURED FOR ENHANCING WORKER MOBILITY

VF IMAGEWEAR, INC., Nash...

1. A pant configured for enhanced mobility, comprising:a first leg portion and a second leg portion, each of the first leg portion and the second leg portion comprising a front panel and a rear panel;
at least one stretch panel located on the rear panel of the first leg portion; and
at least one stretch panel located on the rear panel of the second leg portion;
in which the rear panels of the first leg portion and second leg portion are each divided into an upper region and a lower region by a substantially diagonal seam, the substantially diagonal seam extending from a point at a rear seam of the pant downward to a point at the outer seam of the leg portion;
in which an upper edge of each of the first and second stretch panels coincides with each of the substantially diagonal seams and extends from the point at the rear seam of the pant downward to an outer point located on the rear panel of the leg portion; and
in which each of the stretch panels provides a wearer with enhanced mobility when performing one or more of the following motions: (a) bending over, (b) squatting, (c) kneeling and twisting, (d) reaching forward and up, and (e) big step.

US Pat. No. 10,362,811

SOCK WITH SUPPORT ASSEMBLAGE

SOKSYSTEM, LLC, Beverly ...

1. A sock, comprising:a sock body defined by a toe section, a heel flap, a sole extending between the toe section and the heel flap on a bottom portion of the sock, and an instep extending between the toe section and the heel flap on a top portion of the sock, the toe section and the instep having a first elasticity coefficient;
an arch support assemblage, situated below the instep, in front of the heel flap, and behind the toe, the arch support assemblage adapted to cover an arch region of the sole of the sock excluding the toe section of the sock, the arch support assemblage having a second elasticity coefficient, wherein the second elasticity coefficient is lower than the first elasticity coefficient such that the arch support assemblage is stiffer than the toe, the heel flap, the instep, and the leg of the sock; and
an Achilles support assemblage, adapted to cover an Achilles tendon of a wearer of the sock when worn, the Achilles support assemblage running from a top edge of the heel flap to a top portion of a leg of the sock.

US Pat. No. 10,362,805

WICKLESS CARTOMIZER

Intrepid Brands, LLC, Lo...

1. A wickless cartomizer comprising:(a) a base;
(b) an outer wall extending from the base;
(c) an inner wall extending from the base;
(d) a vapor exit opening defined by the inner wall;
(e) a heating element disposed in the inner wall; and
an electrical connector disposed in the base, wherein the electrical connector is electrically coupled with the heating element.

US Pat. No. 10,362,803

ELECTRONIC VAPORIZER HAVING REDUCED PARTICLE SIZE

EVOLV, LLC, Ashtabula, O...

1. An electronic vaporizer device for simulating smoking, the device comprising:at least one aerosol generating structure, comprised of:
a first heating element;
a wick configured to supply a liquid to the first heating element, the first heating element aerosolizing the liquid into an aerosol;
an air channel configured to carry the aerosol generated at the first heating element away from the first heating element;
at least one second heating structure comprised of:
a second heating element;
the second heating element being downstream relative to the first heating element to apply heat to the aerosol,
wherein the at least one second heating structure does not receive the liquid from the wick;
a connector; and
a controller that is to be removably coupled to, and separable from the aerosol generating structure by the connector, the controller being further connected to a power source providing electrical power, the controller having at least two regulated outputs which can supply the electrical power to the first heating element and the second heating element concurrently with independent control of each output, wherein the controller independently controls at least the output that supplies electrical power to the second heating element based on one or more relationships between a measured resistance of the second heating element during operation, and a known resistance of the second heating element at one or more specific temperatures;
wherein the at least one aerosol generating structure forms the aerosol having a particle size distribution in a controllable manner; and wherein the at least one second heating structure is downstream of the first heating element, the second heating element applying additional heat to the aerosol to at least change the particle size distribution within the aerosol to generate an output aerosol in a controllable manner.

US Pat. No. 10,362,799

DEVICE FOR SEPARATING STALKS OF FRUITS GROUPED IN BUNCHES AND METHOD FOR SEPARATING STALKS OF FRUITS GROUPED IN BUNCHES

RODA IBERICA, S.L., Alzi...

1. A device for separating stalks of fruits grouped in bunches, the device comprising:a fruit reception compartment, where the fruits and a liquid are configured to be located, the fruit reception compartment being connected to a fruit suction area and a liquid suction area, the liquid suction area comprising an orifice connected to a pump for suction of at least a part of the liquid,
a narrowing comprising an outlet which feeds into a channel, and
a pipe configured to carry the at least the part of the liquid from the pump into the channel,
wherein the device is configured to:
produce a depression for dragging the fruits and the liquid located in the fruit suction area through the narrowing to the channel
such that the fruits and the liquid mix with the at least the part of the liquid flowing at a first speed from the pump, and a mixture of the at least the part of the liquid flowing at the first speed from the pump and the liquid flowing at a second speed from the fruit suction area generates turbulence that produces separation of the stalks from the fruits, and
wherein the first speed is higher than the second speed.

US Pat. No. 10,362,798

ROASTING SYSTEM WITH CLEAN EMISSIONS AND HIGH THERMAL EFFICIENCY

Bellwether Coffee Co., B...

1. A bean roasting system, comprising:a roasting chamber coupled to a recirculating gas flow path;
a blower coupled to the recirculating gas flow path, the blower configured to provide a flow stream of gas through the recirculating gas flow path;
a variable diverter coupled to the recirculating gas flow path, the variable diverter configured to split the gas flow path into at least two flow paths including a treated flow path and a bypass flow path, the treated flow path including a series arrangement of a gas heater and a catalytic converter, the variable diverter configured to control a percentage of a flow stream of gas that is diverted into the bypass flow path; and
a controller configured to activate a plurality of different predetermined operating modes for the bean roasting system by controlling a state of the variable diverter and a state of the heater, gas flows out of the roasting chamber through the variable diverter and through the treated flow path and bypass flow path before returning to the roasting chamber along the recirculating flow path, the variable diverter is configured such that (1) the percentage of the flow stream of gas that is diverted into the bypass flow path controls a temperature in the roasting chamber as compared to a temperature in the catalytic converter, and (2) the temperature in the roasting chamber decreases relative to the temperature in the catalytic converter as the percentage of the flow stream of gas that is diverted into the bypass flow path is increased.

US Pat. No. 10,362,795

COLLAPSIBLE FOOD PREPARATION DEVICE

Alan Backus, Los Angeles...

1. A food preparation device using heated air, comprising:a heat source configured to heat air to food preparation temperatures;
a base enclosure configured to contain the heat source;
a first tray, stacked above the base enclosure, and including a generally flat floor configured to support foods to be processed, the floor being perforated to allow air passage from one side of the floor to the other side of the floor;
the floor being generally rectangular and comprising four generally straight edges;
the floor includes four generally planar hinged side walls, one each hinged to each of the four generally straight edges;
each of the four hinged side walls configured to rotate about its associated hinge axes from a generally horizontal disposition to a generally vertical disposition;
a second tray having substantially the same construction as the first tray,
the second tray configured to stack above the first tray when the four hinged side walls on the first tray are in their generally vertical dispositions;
wherein, when the heat source is activated during food preparation, the four hinged side walls on the first tray and the four hinged side walls on the second tray which is stacked above the first tray, are each in their vertical dispositions; and
wherein, when the heat source is not activated, and the device is not preparing food the four hinged side walls on the first tray and the four hinged side walls on the second tray are each oriented in their horizontal dispositions.

US Pat. No. 10,362,780

OXYGEN SUPPLY FOR ORGAN PERFUSION SYSTEMS

Organox Limited, Oxford ...

1. A perfusion system for the perfusion of an organ, the system comprising:a perfusion fluid circuit for circulating perfusion fluid through the organ;
an oxygenator for adding oxygen into the perfusion fluid, the oxygenator comprising a duct to carry the perfusion fluid, an oxygen chamber, and a permeable membrane between the duct and the oxygen chamber;
an oxygen supply arranged to supply oxygen to the oxygenator, wherein the oxygen supply comprises an oxygen concentrator, the oxygen concentrator comprising an inlet arranged to receive gas in the form of air, a compressor arranged in the inlet, and a nitrogen extractor arranged to extract nitrogen from the gas thereby to increase the oxygen concentration of the gas;
an air supply arranged to supply air to the oxygenator;
a carbon dioxide sensor arranged to measure a carbon dioxide content of the perfusion fluid;
an air control valve arranged to control the flow rate of air from an air supply to the oxygen chamber;
an oxygen control valve arranged to control the flow rate of oxygen from the oxygen concentrator to the oxygen chamber;
an oxygen sensor arranged to measure an oxygen content of the perfusion fluid; and
a controller arranged to define a first target range for said oxygen content, monitor the measured oxygen content and to control the oxygen control valve and the compressor in response to the measured oxygen content thereby to maintain the oxygen content within the first target range, and to define a second target range for said carbon dioxide content, to monitor the measured carbon dioxide content and to control the air control valve in response to the measured carbon dioxide content thereby to maintain the carbon dioxide content within the second target range.

US Pat. No. 10,362,773

AUTOMATIC RETRACTABLE FLOAT

RETRACT A FLOAT PTY LTD.,...

1. An automatic retractable float comprising:a body which floats in water;
the body comprising two halves connected to a central portion;
the central portion having a top handle, a pair of side handles and a line housing disposed about the outer surface, with a depression located under each side handle,
wherein about the outer surface of the central portion the line housing is positioned substantially opposite the top handle and the side handles are positioned substantially opposite each other such that each side handle is approximately midway between the top handle and the line housing and
wherein the line housing includes a conduit that passes through the outer surface of the central portion and provides access to an interior of the body;
each of the two halves having a pair of depressions positioned such that when each half is attached to the central portion, the pair of depressions are joined with the corresponding depression under each side handle;
an automatic retraction and extension mechanism contained within the interior of the body, the automatic retraction and extension mechanism including a spring mechanism for automatically extending and retracting a line from the body; and
at least one electronic device in communication with a mobile device such that the electronic device shares information or data with the mobile device.

US Pat. No. 10,362,765

PET TOY WITH SQUEAKER MECHANISM

Otomik Products, Inc., C...

1. An animal toy, comprising:a body member defining a cavity and including a sidewall, the sidewall defining a first opening in fluid communication with the cavity, the sidewall defining a second opening in fluid communication with the cavity, the first and second openings being disposed on an outer periphery of the body member, the first opening being different than the second opening; and
a squeaker member defining a lumen and configured to produce a sound in response to air passing through the lumen, the squeaker member being coupled to the body member such that at least a portion of the squeaker member is disposed within the cavity defined by the body member, the squeaker member including a switch configured to be moved from a first position to a second position, the switch being configured to prevent passing of air through the lumen when the switch is in the first position.

US Pat. No. 10,362,735

HARVESTING ATTACHMENT FOR A HARVESTER

BISO Schrattenecker GmbH,...

1. A harvesting attachment having a frame comprising:an elongated rear wall formed as an extrusion profile;
an elongated base wall formed as an extrusion profile;
an elongated curved connection wall curved in cross section formed as an extrusion profile;
wherein each of said rear wall, base wall and curved connection wall have a front wall and a back wall.

US Pat. No. 10,362,722

SOIL PROCESSING DEVICE

REDEXIM HANDEL-EN EXPLOIT...

1. A mobile soil working device comprising:a machine frame,
a drive,
at least one support arm configured to be movable up and down by the drive and pivotably supported by the machine frame,
at least one insertion tool configured to be pivotable relative to the support arm about a first pivot axis and movable in an upward direction and a downward direction by the support arm, the insertion tool adapted to be inserted into the soil and pulled from the soil,
wherein, prior to insertion into the soil, the insertion tool is configured to be disposed in an initial position under a predefined insertion angle, and is configured to carry out a pivot movement from the initial position, the pivot movement being superposed over up-and-down movement of the insertion tool, about the first pivot axis in a first pivoting direction in the soil on the basis of movement of the machine frame in a direction of travel,
at least one returning mechanism which is coupled to the machine frame at a first end and to the insertion tool at a second end, the returning mechanism having a first biasing element and a second biasing element, wherein the first biasing element is a returning element configured to move the insertion tool back into the initial position by pivoting the insertion tool in a second pivoting direction opposite the first pivoting direction after the insertion tool exits the soil,
wherein the second biasing element is an independent spring device in addition to the returning element, said spring device allowing the insertion tool to be pivoted in the second pivoting direction beyond the initial position such that the insertion tool is pivoted in the second pivoting direction beyond the initial position upon hitting a hard object in the soil.

US Pat. No. 10,362,721

TILLAGE DEVICE FOR AGRICULTURAL MACHINERY OR IMPLEMENTS TO REDUCE COMPACTION CAUSED BY WHEELS IN A FIELD

AGRICULTURE CONCEPTS, LLC...

1. A system for tilling compression marks formed in soil of a field by agricultural machinery or equipment having a plurality of compaction forming members, the system comprising:a plurality of roller assemblies;
each of the plurality of roller assemblies having a plurality of blade assemblies positioned in spaced relation to one another;
each of the plurality of roller assemblies operatively connected to a frame member;
a plurality of row units;
wherein the plurality of row units are configured to plant seeds in the soil of the field;
wherein each of the plurality of roller assemblies are positioned between a pair of adjacent row units configured to plant seeds in the soil of the field;
wherein the plurality of roller assemblies are configured to rotate;
a movement device connected to each of the plurality of roller assemblies wherein when activated the movement device moves the associated roller assembly between a disengaged position, where the roller assembly does not penetrate the soil, and an engaged position, where the roller assembly does penetrate and till the soil;
each of the plurality of roller assemblies each having at least one guard positioned in spaced relation to the associated roller assembly;
wherein each guard is configured to deflect dirt that is kicked up during the tilling process;
wherein the plurality of roller assemblies are positioned behind and in alignment with a plurality of compaction forming members of the agricultural machinery or equipment;
wherein when the agricultural machinery or equipment moves through the field the compaction forming members form compression marks in the soil of the field;
wherein when in an engaged position, when the agricultural machinery or equipment moves through the field, the plurality of roller assemblies till the compression marks formed by the compaction forming members;
wherein when in an engaged position, when the agricultural machinery or equipment moves through the field, the plurality of roller assemblies till the compression marks formed by the compaction forming members the at least one guard associated with each roller assembly deflects dirt that is kicked up during the tilling process;
wherein positioning each of the plurality of roller assemblies behind and in alignment with a compaction forming member of the agricultural machinery or equipment facilitates tilling of the area behind and in alignment with the aligned compaction forming member while leaving the area between the compaction forming members untilled;
wherein the at least one guard associated with each roller assembly is configured to prevent dirt kicked up during the tilling process from landing outside of the tilled area which is behind and in alignment with the aligned compaction forming member.
US Pat. No. 10,363,300

FMDV AND E2 FUSION PROTEINS AND USES THEREOF

BOEHRINGER INGELHEIM ANIM...

1. A method of vaccinating a host susceptible to ovine, bovine, caprine, or swine Foot-and-Mouth Disease Virus (FMDV), or protecting or preventing the host against FMDV infection, or eliciting a protective immune response in a host, comprising at least one administration of a composition or vaccine comprising an FMDV antigen or polypeptide; wherein the FMDV antigen or polypeptide has at least 90% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 4, 6, 8, 10, 12 or 14.
US Pat. No. 10,362,789

METHOD FOR CONTROLLING PESTS

SUMITOMO CHEMICAL COMPANY...

1. A method for controlling a weed in a field of soybean, corn or cotton, comprising applying at least one PPO-inhibiting compound selected from the group consisting of sulfentrazone, saflufenacil, and fomesafen-sodium to a field before, at or after seeding with a seed of soybean, corn or cotton treated with one or more nematicides selected from the group consisting of abamectin and Bacillus firmus.
US Pat. No. 10,363,303

MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME

VERNDARI, INC., Sacramen...

1. A microneedle device for administering a polypeptide, comprising:(a) a dehydrated composition comprising the polypeptide; and
(b) a substrate comprising a sheet and a plurality of microneedles extending therefrom, each microneedle of the plurality of microneedles comprising a tip, a base, a hinge at the base connecting the microneedle to the sheet, and a well comprising the dehydrated composition.
US Pat. No. 10,363,308

SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION

SNIPR Technologies Limite...

1. A method for treating a cancer in a patient, wherein the method comprises(a) exposing a microbiota in the patient to a guided nuclease to selectively target the genome of cells of a first species in the microbiota using the guided nuclease, wherein the first species is a bacterial or archaeal species; and simultaneously or sequentially administering to the patient an effective amount of an immunotherapy; and
(b) allowing the guided nuclease to cut one or more target nucleotide sequences comprised by first cells of a first strain of the first species, thereby killing the first cells or reducing the growth thereof, whereby the proportion of the first cells comprised by the microbiota is reduced;wherein(c) the selective targeting avoids targeting second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells; and
(d) the reducing of the proportion of the first cells modulates immune cells in the patient, whereby the efficacy of the immunotherapy is enhanced for treatment of the cancer in the patient.
US Pat. No. 10,364,332

HIGH TG EPOXY FORMULATION WITH GOOD THERMAL PROPERTIES

ISOLA USA CORP., Chandle...

1. A prepreg comprising a b-staged varnish composition including:a multi-functional epoxy wherein the multi-functional resin is not an eight-functional bisphenol-A novolac epoxy resin;
an eight-functional bisphenol-A novolac epoxy resin;
a bifunctional epoxy resin;
a hardener selected from 4,4?-diaminodiphenylsulfone, 3,3?-diaminodiphenylsulfone and mixtures thereof; and
decabromodiphenylethane wherein the prepreg is capable of being c-staged to a composite having a DMA Tg in excess of 280° C. and a T288 time in excess of 20 minutes.
US Pat. No. 10,363,314

SPRAYABLE TOPICAL CARRIER AND COMPOSITION COMPRISING PHOSPHATIDYLCHOLINE

LIPIDOR AB, Stockholm (S...

1. Pharmaceutical or cosmetic carrier for topical administration, said carrier comprisingfrom 2%-40% by weight of phosphatidylcholine;
from 2%-25% by weight of monoglyceride;
from 2% to 30% by weight of fatty acid ester of C1-C3 alcohol; and
volatile solvent selected from the group consisting of:
ethanol; ethanol and C3-C4 alcohol; ethanol and volatile silicone oil; and ethanol, C3-C4 alcohol and volatile silicone oil.
US Pat. No. 10,363,316

PHARMACEUTICAL FORMULATION COMPRISING NSAID AND CYCLODEXTRIN

RECKITT BENCKISER HEALTHC...

1. A liquid throat spray composition for topical application to a sore throat consisting essentially of an aqueous solution of at least 1% w/v of flurbiprofen, a cyclodextrin, and a pharmaceutically acceptable buffer,wherein the molar ratio of the NSAID to the cyclodextrin is between 1:0.5 and 1:1.5; and
wherein the composition is provided in a unit volume of up to about 2 ml.
US Pat. No. 10,363,572

METHOD FOR PRODUCING A MULTICOAT PAINT SYSTEM ON PLASTICS SUBSTRATES

BASF Coatings GmbH, Muen...

1. A method for producing a paint system on a plastics substrate, the method comprising:(1) producing a basecoat film or a plurality of directly successive basecoat films on the plastics substrate by applying an aqueous basecoat material to the substrate or directly successively applying a plurality of basecoat materials to the substrate;
(2) producing a clearcoat film directly on the basecoat film or a topmost basecoat film by applying a clearcoat material directly to the basecoat film or the topmost basecoat film; and
(3) jointly curing the basecoat film and the clearcoat film or the basecoat films and the clearcoat film,
wherein:
the aqueous basecoat material or at least one of the basecoat materials comprises at least one aqueous polyurethane-polyurea dispersion comprising polyurethane-polyurea particles;
the polyurethane-polyurea particles in the dispersion comprise anionic groups, groups which can be converted into anionic groups, or both;
the polyurethane-polyurea particles comprise, in each case in reacted form:
at least one polyurethane prepolymer containing isocyanate groups and comprising the anionic groups, the groups which can be converted into anionic groups, or both; and
at least one polyamine comprising two primary amino groups and one or two secondary amino groups;
the polyurethane prepolymer does not contain subunits formed from a monoalcohol;
the polyurethane-polyurea particles present in the dispersion have an average particle size of 40 to 2000 nm; and
a gel fraction of the polyurethane-polyurea particles present in the dispersion is at least 50%.
US Pat. No. 10,364,342

TIRE HAVING TREAD FOR LOW TEMPERATURE PERFORMANCE AND WET TRACTION

1. A pneumatic tire having a circumferential rubber tread of a rubber composition comprised of, based on parts by weight per 100 parts by weight elastomer (phr):(A) 100 parts by weight of a combination of conjugated diene-based elastomers comprised of:
(1) about 10 to about 50 phr of an organic solvent polymerization prepared high Tg styrene/butadiene elastomer having a Tg in a range of from about ?40° C. to about ?30° C. with a styrene content in a range of from about 30 to about 35 weight percent wherein said high Tg S-SBR is extended with from about 10 to about 38 parts by weight per 100 parts of said high Tg styrene/butadiene elastomer of triglyceride vegetable oil,
(2) about 10 to about 50 phr of aqueous emulsion polymerization prepared styrene/butadiene elastomer having a Tg in a range of from about ?65° C. to about ?45° C. with a styrene content in a range of from about 15 to about 30 weight percent, and
(3) about 20 to about 60 phr of cis 1,4-polybutadiene rubber having a cis 1,4-isomeric content of at least about 95 percent and having a Tg in a range of from about ?100° C. to about ?108° C.,
(B) about 50 to about 250 phr of rubber reinforcing filler comprised of a combination of precipitated silica derived from silicon dioxide based inorganic sand or from silicon dioxide containing rice husks and rubber reinforcing carbon black where said reinforcing filler is comprised of from about 2 to about 10 phr of said rubber reinforcing carbon black, wherein said precipitated silica of said reinforcing filler is comprised of at least one of:
(1) pre-hydrophobated precipitated silica comprised of precipitated silica pre-hydrophobated with an alkoxyorganomercaptosilane or bis(3-triethoxysilylpropyl) polysulfide containing an average of from about 2 about 4 connecting sulfur atoms in its polysulfidic bridge to form a composite thereof,
(2) precipitated silica having a nitrogen surface area in a range of from about 140 to about 220 m2/g together with a silica coupler having a moiety reactive with hydroxyl groups on said precipitated silica and another different moiety interactive with said diene-based elastomers, and
(3) precipitated silica having a nitrogen surface area in a range of from about 90 to about 130 m2/g together with a silica coupler having a moiety reactive with hydroxyl groups on said precipitated silica and another different moiety interactive with said diene-based elastomers,
(C) about 5 to about 45 phr of traction promoting resin comprised of at least one of terpene, coumarone indene and styrene-alphamethylstyrene resins having a softening point within a range of from about 60° C. to about 150° C.
US Pat. No. 10,363,319

GLYCOCONJUGATES AND METHODS FOR THEIR USE

THE BOARD OF REGENTS OF T...

1. A neoglycoconjugate comprising a trisaccharide coupled to a carrier, wherein the trisaccharide is Gal?(1,3)Gal?(1,4)GlcNAc?.
US Pat. No. 10,367,160

LIGHT-EMITTING ELEMENT

Semiconductor Energy Labo...

1. A light-emitting element comprising:a light-emitting layer comprising a first compound, a second compound, and a guest material,
wherein the first compound and the second compound are capable of forming an exciplex, and
wherein an emission peak wavelength of the exciplex is longer than or equal to a peak wavelength of an absorption band located on the longest wavelength side of an absorption spectrum of the guest material.
US Pat. No. 10,363,322

NON-ALCOHOLIC FATTY LIVER REGULATOR 14-3-3 PROTEIN

Korea University Research...

1. A method of treating non-alcoholic fatty liver, the method comprising administering an inhibitor against a 14-3-3? gene to a subject to decrease transcriptional activity of PPAR?2,wherein the inhibitor comprises an antisense oligonucleotide, siRNA, shRNA or miRNA against the 14-3-3? gene, or a vector comprising the same.
US Pat. No. 10,364,346

ABS-BASED RESIN COMPOSITION AND METHOD ARTICLE MANUFACTURED THEREFROM

LG CHEM, LTD., Seoul (KR...

1. A method of preparing an ABS-based resin composition, the method comprising: a step of feeding (a) 22.5 to 50% by weight of a vinyl cyan compound-conjugated diene-based rubber-like polymer-aromatic vinyl compound copolymer resin, wherein (a) the vinyl cyan compound-conjugated diene-based rubber-like polymer-aromatic vinyl compound copolymer resin is prepared by graft-polymerizing 40 to 70% by weight of a conjugated diene-based rubber-like polymer having an average particle diameter of 2500 to 3500 ? with 8 to 48% by weight of an aromatic vinyl compound and 6 to 24% by weight of a vinyl cyan compound; (b) 47.5 to 75% by weight of an aromatic vinyl compound-vinyl cyan compound copolymer resin; (c) 1 to 6% by weight of a polyether ester amide resin; and (d) 1.5 to 3% by weight of an ethoxylated alkylamine-based antistatic agent into an extruder, followed by mixing and extruding in a 180 to 220° C. barrel.
US Pat. No. 10,364,361

WEATHERPROOF AQUEOUS WOOD COATINGS

AKZO NOBEL CHEMICALS INTE...

1. An aqueous coating composition comprising:an aqueous solvent,
a fatty amine quaternary having the following structure:
R1R2R3R4N+X?
 wherein R1, R2, R3, and R4 are independently chosen from saturated or unsaturated, linear or branched, substituted or unsubstituted, alkyl, aralkyl, or alkenyl groups, comprising from 1 to 30 carbon atoms, wherein at least one of R1, R2, R3, and R4 includes both a C12-C30 group and ethoxy and/or propoxy groups, wherein X? is an anion from an inorganic or organic acid, and wherein the number average molecular weight of the fatty amine quaternary is between about 100 g/mol and about 1500 g/mol, and
binder in an amount of between 40% to 90% by weight of the aqueous coating composition.
US Pat. No. 10,364,365

CURABLE COLORED INKS FOR MAKING COLORED SILICONE HYDROGEL LENSES

Novartis AG, Basel (CH)

1. An ink for making colored silicone hydrogel contact lenses, comprising at least a pigment, a polymeric dispersant, a synergist, a solvent and an actinically or thermally curable silicone-containing binder polymer including ethylenically unsaturated groups and segments derived from at least one silicone-containing vinylic monomer or macromer, wherein the synergist is selected from a group consisting of sulfonated Cu-phthalocyanine, copper phthalocyaninesulfonic acid and combinations thereof, wherein the ink is substantially free of water and has capability to be cured actinically or thermally to form a colored coat on a contact lens, wherein the ink is characterized by having a longer print life using a pad-printing system by at least 30% comparing to the ink which has the same composition except with no polymeric dispersant, wherein ink life is a number of printed parts that can be achieved in a print cycle.
US Pat. No. 10,364,367

NON-NEWTONIAN INKJET INKS

Hewett-Packard Developmen...

1. A non-Newtonian inkjet ink, comprising:a first metal oxide nanoparticle selected from the group consisting of substantially spherical or non-spherical silica particles, alumina particles, zinc oxide particles, iron oxide particles, titanium oxide particles, and combinations thereof, the first metal oxide nanoparticle having a particle size of 10 nm or less, and the first metal oxide nanoparticle present in an amount ranging from about 5% to about 15% by weight based on a total weight of the non-Newtonian inkjet ink;
a second metal oxide nanoparticle selected from the group consisting of alumina, titanium oxide, substantially spherical silica, anisotropic silica, and combinations thereof, the second metal oxide nanoparticle having at least one dimension greater than 10 nm, and the second metal oxide nanoparticle present in an amount ranging from 0.25% to 10% by weight based on the total weight of the non-Newtonian inkjet ink;
a colorant in an amount ranging from about 0.5% to about 10% by weight based on the total weight of the non-Newtonian inkjet ink;
an organic solvent in an amount ranging from about 5% to about 50% by weight based on the total weight of the non-Newtonian inkjet ink; and
a balance of water.
US Pat. No. 10,364,377

ADHESIVE COMPOSITIONS MADE FROM PROPYLENE-BASED POLYMERS AND CRYSTALLINE C2/C3 HOMOPOLYMER

ExxonMobil Chemical Paten...

1. An adhesive composition comprising:a polymer blend comprising a first propylene-based polymer, wherein the first propylene-based polymer is a homopolymer of propylene or a copolymer of propylene and ethylene or a C4 to C10 alpha-olefin, and a second propylene-based polymer, wherein the second propylene-based polymer is a homopolymer of propylene or a copolymer of propylene and ethylene or a C4 to C10 alpha-olefin; wherein the second propylene-based polymer is different than the first propylene-based polymer; wherein the polymer blend has a melt viscosity, measured at 190° C. and determined according to ASTM D-3236, of about 1,000 cP to about 5,000 cP;
a propylene polymer, wherein the propylene polymer is a homopolymer of propylene or a copolymer of propylene units with from about 0.5 to about 4 wt. % ethylene of C4 to C10 alpha-olefin comonomer derived units, and wherein the propylene polymer has a melt flow rate, measured according to ASTM D-1238 at 230° C. and 2.16 kg. of less than about 1,000 g/10 min; and
wherein the adhesive composition is substantially free of a functionalized polyolefin, wherein the functionalized polyolefin is selected from at least one of a maleic anhydride-modified polypropylene and a maleic anhydride-modified polypropylene wax.
US Pat. No. 10,364,378

POLARIZING STRUCTURE COMPRISING A GLYOXAL ADHESIVE SYSTEM AND POLARIZED LENS COMPRISING IT

ESSILOR INTERNATIONAL, C...

1. A polarizing structure comprising:a polarizing film having faces; and
a protective film provided on both faces of the polarizing film with an adhesive layer;
wherein the adhesive layer is a glyoxal-based adhesive obtained from a glyoxal water solution comprising:
about 5% by weight of glyoxal; and
about 5% by weight of polyvinyl alcohol (PVOH) polymer
at least one of the protective films comprises PC or PMMA; and
wherein a first face of the at least one protective film is oriented towards the polarizing film and further comprises an adhesion primer structure.
US Pat. No. 10,367,199

CATHODE ACTIVE MATERIAL, LITHIUM SECONDARY BATTERY HAVING SAME, AND METHOD FOR PREPARING SAME

Korea Electronics Technol...

1. A cathode active material for lithium secondary batteries which is represented by Chemical Formula 1 below and is obtained by coating a dissimilar metal (M) on a surface of a transition metal precursor comprising Ni, Co and Mn and then heat-treating the transition metal precursor together with a lithium source so that a portion of Ni, Co and Mn is substituted with the dissimilar metal (M):LiNiaCobMncMdO2  [Chemical Formula 1 ]
wherein 0.65?a ?0.7, 0
US Pat. No. 10,367,204

ALUMINUM ALLOY FOIL FOR ELECTRODE CURRENT COLLECTORS AND MANUFACTURING METHOD THEREOF

UACJ Corporation, Tokyo ...

1. An aluminum alloy foil for an electrode current collector, comprising 0.03 to 0.1 mass % (hereinafter, “mass %” is simply referred to as “%”) of Fe, 0.01 to 0.1% of Si, and 0.0001 to 0.01% of Cu, with the rest being Al and unavoidable impurities, wherein the aluminum alloy foil after final cold rolling has a tensile strength of 180 MPa or higher, a 0.2% yield strength of 160 MPa or higher, and an electrical conductivity of 60% IACS or higher; and the aluminum alloy foil has a tensile strength of 170 MPa or higher and a 0.2% yield strength of 150 MPa or higher even after the aluminum alloy foil is subjected to heat treatment at any of 120° C. for 24 hours, 140° C. for 3 hours, and 160° C. for 15 minutes.
US Pat. No. 10,364,403

MARINE DIESEL CYLINDER LUBRICANT OIL COMPOSITIONS

Chevron Oronite Technolog...

1. A marine diesel cylinder lubricating oil composition which comprises:(a) a major amount of one or more Group I basestocks, and
(b) a detergent composition comprising:
(i) about 5 to about 15 wt. % on an actives basis, based on the total weight of the marine diesel cylinder lubricating oil composition, of one or more alkaline earth metal salts of an alkyl-substituted hydroxyaromatic carboxylic acid having a total base number (TBN) of about 100 to about 250, wherein the alkyl-substituted moiety of the alkaline earth metal salt of an alkyl-substituted hydroxyaromatic carboxylic acid is a C12 to C28 alkyl group; and
(ii) about 5 to about 16 wt. % on an actives basis, based on the total weight of the marine diesel cylinder lubricating oil composition, of one or more high overbased calcium alkyl toluene sulfonic acids or salts thereof having a TBN of greater than 250 to about 550; wherein the toluene moiety of the calcium alkyl toluene sulfonic acids or salts thereof contains no hydroxyl groups, and further wherein the alkyl moiety of the calcium alkyl toluene sulfonic acids or salts thereof is a C12 to C40 alkyl group; and
wherein the marine diesel cylinder lubricating oil composition has a TBN of about 55 to about 80.
US Pat. No. 10,364,415

1,4-DIOXANE-DEGRADING BACTERIA CULTURE METHOD, MEDIUM, AND 1,4-DIOXANE TREATMENT METHOD USING 1,4-DIOXANE-DEGRADING BACTERIA

TAISEI CORPORATION, Toky...

1. A 1,4-dioxane-degrading bacteria culture method comprising culturing/incubating 1,4-dioxane-degrading bacteria with a medium containing diethylene glycol at a concentration of 1.0 wt % or more and 10.0 wt % or less, thereby multiplying the 1,4-dioxane-degrading bacteria, wherein the 1,4-dioxane-degrading bacteria are at least one of Mycobacterium sp. D11 (Accession Number: NITE BP-01926) or Pseudonocardia sp. D17 (Accession Number: NITE BP-01927).
US Pat. No. 10,364,421

MODIFIED GLUCOAMYLASE ENZYMES AND YEAST STRAINS HAVING ENHANCED BIOPRODUCT PRODUCTION

CARGILL, INCORPORATED, W...

1. A polypeptide comprising (a) a secretion signal amino acid sequence having 90% or greater identity to SEQ ID NO:10 or SEQ ID NO:11 and (b) a glucoamylase amino acid sequence from a yeast, fungal, or bacterial glucoamylase polypeptide, wherein the polypeptide has glucoamylase activity, andwherein the polypeptide comprises SEQ ID NO: 13.
US Pat. No. 10,364,424

FACTOR X MUTANTS

LABORATOIRE FRANCAIS DU F...

1. A protein, comprising:a mutated sequence of SEQ ID No. 1, said mutated sequence of SEQ ID No. 1 comprising mutation B wherein: mutation B consists of insertion of DFLAEGLTPR (SEQ ID NO: 159) between amino acids 52 and 53 of SEQ ID No. 1.
US Pat. No. 10,364,425

RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS

LABORATOIRE FRANCAIS DU F...

1. A composition comprising recombinant Factor VII (FVII), produced by a transgenic female rabbit,wherein each molecule of FVII of the composition exhibits glycan moieties and two N-glycosylation sites,
wherein among all the molecules of FVII of the composition, the proportion of Gal?1,3Gal glycan moieties is between 0 and 4%,
wherein the molecules of FVII of the composition do not comprise sialic acid bound in ?2-3 links,
wherein among all the glycan moieties bound to N-glycosylation sites of the FVII of the composition, more than 50% of the glycan moieties are biantennary, monosialylated, glycan moieties,
wherein the molecules of FVII of the composition exhibit two O-glycosylation sites at position Ser52 and Ser60
wherein the molecules of FVII of the composition exhibit nine ?-carboxylated N-terminal glutamic acids, and
wherein the molecules of FVII of the composition exhibit 12 specific disulfide bridges.
US Pat. No. 10,364,426

PROCESS FOR REDUCING CELL DEATH AND INCREASING GROWTH OF AN ALGAL CULTURE

MISSING LINK TECHNOLOGY, ...

1. A process for reducing cell death and increasing growth of an algal culture, the process comprising:mixing the algal culture with water in a first reactor, the first reactor being a continuously stirred reactor, the step of mixing comprising:
continually circulating nutrients and the algal culture in a toroidal pattern and in a bottom-to-top pattern within said first reactor;
strobing light onto the mixture of algal culture and water for a period of time at a frequency of between 10 Hz and 40 Hz and between twenty flashes per second and eighty flashes per second;
flowing the strobed mixture of the algal culture and water from said first reactor for a period of time to a second reactor, the second reactor being a plug flow reactor, the step of flowing further comprising:
discharging the strobed mixture through a central drain of the first reactor to decrease fluid velocity of the strobed mixture and obtain a Reynolds Number (NRE) of less than 2000 is the second reactor;
discharging the strobed mixture from the second reactor; and
reducing cell death and increasing growth of said algal culture at a growth rate exceeding 120 grams/m2/day.
US Pat. No. 10,364,433

MODULATION OF AGPAT5 EXPRESSION

The Regents of the Univer...

1. A method of reducing insulin, glucose, and/or free fatty acid levels in blood, triglyceride levels in the liver and/or the ratio of fat to body weight of an animal comprising administering a compound comprising an antisense oligonucleotide targeted to nucleic acid encoding human AGPAT5 wherein the level of insulin, glucose and/or free fatty acid in the blood, the level of triglycerides in the liver and/or the ratio of fat to body weight of the animal is/are reduced.
US Pat. No. 10,364,434

COMPOSITIONS AND METHODS OF BIOSYNTHESIZING CAROTENOIDS AND THEIR DERIVATIVES

ARCH INNOTEK, LLC, St. L...

1. A recombinant microorganism comprising a nucleic acid construct comprising:a) a nucleic acid sequence encoding a lycopene s-cyclase enzyme encoded by LCYe from Lactuca sativa; and
b) a nucleic acid sequence encoding a carotenoid cleavage dioxygenase enzyme encoded by CCD1 from Daucus carota:
wherein the nucleic add sequences are operably linked to one or more expression control sequences, and wherein the microorganism further comprises lycopene.
US Pat. No. 10,364,187

JAMB SPRAY MIXES INCLUDING FUSED SILICA AND METHODS OF UTILIZING THE MIXES

Resco Products, Inc., Pi...

1. A jamb spray mix comprising:0.1% to 10% phosphate by weight based on total weight of dry ingredients in the mix;
5% to 15% plasticizer based on total weight of dry ingredients in the mix;
the balance of dry ingredients including fused silica particles and impurities; and
at least 20% water by weight based on total weight of the mix.
US Pat. No. 10,364,444

SACCHAROMYCES CEREVISIAE YEAST STRAINS AND METHODS OF USE THEREOF

Microbiogen Pty. Ltd., S...

1. A process for producing ethanol from starch-containing material, the process comprising the steps of:i) liquefying the starch-containing material at a temperature above the initial gelatinization temperature using an alpha-amylase;
ii) saccharifying using a glucoamylase;
iii) fermenting using a fermenting organism;wherein the fermenting organism is:Saccharomyces cerevisiae MBG4930 (deposited under Accession No. V15/004035 at National Measurement Institute, Victoria, Australia);
Saccharomyces cerevisiae MBG4931 (deposited under Accession No. V15/004036 at National Measurement Institute, Victoria, Australia); or
Saccharomyces cerevisiae MBG4932 (deposited under Accession No. V15/004037 at National Measurement Institute, Victoria, Australia).
US Pat. No. 10,365,213

RELIABLE FLUORESCENCE CORRECTION METHOD FOR TWO-COLOR MEASUREMENT FLUORESCENCE SYSTEM

CapitalBio Corporation, ...

1. A microarray chip for use in a two-color fluorescence measurement system, comprising three kinds of standard spots separate from each other on the microarray chip that are useful for determining correction factors for fluorescence measurements with the system, wherein the three standard spots comprise:standard spot 1 comprising the donor fluorophore and none of the acceptor fluorophore used in the two-color fluorescence measurement system, wherein the donor fluorophore is immobilized on the microarray chip,
standard spot 2 comprising the acceptor fluorophore and none of the donor fluorophore used in the two-color fluorescence measurement system, wherein the acceptor fluorophore is immobilized on the microarray chip,
wherein the acceptor fluorophore in standard spot 2 is present in the same molar amount as the donor fluorophore in standard spot 1, and
standard spot 3 comprising both the donor and the acceptor fluorophores immobilized on the microarray chip, wherein the molar amount of the donor fluorophore in standard spot 3 equals the molar amount of the acceptor fluorophore in standard spot 3.
US Pat. No. 10,364,446

STREPTOMYCES PSAMMOTICUS AND METHODS OF USING THE SAME FOR VANILLIN PRODUCTION

XIAMEN OAMIC BIOTECHNOLOG...

1. A method for producing vanillin using Streptomyces psammoticus strain OMK-4 having preservation number CCTCC M 2015329, wherein the method comprises the steps of:1) strain activation;
2) seed culture; and
3) fermentation of ferulic acid to produce vanillinwherein strain activation step 1 comprises:under aseptic conditions, a full inoculation loop of strain OMK-4 from a glycerin stock tube is spread evenly over an agar slant and cultured in a biochemical incubator at 26-30° C. for 24-48 hours, and wherein by percentage of weight, the agar slant comprises the following components:soluble starch 1.0-3.5%, KH2PO4 0.1-1.0%, NaCl 0.05-0.3% and yeast extract powder 0.1-1.0%, andwherein seed culture step 2 comprises:under aseptic conditions, a full inoculation loop of well-grown OMK-4 cells from the ager slant in step 1 is inoculated into a seed culture medium having an initial pH value of 5-8 and cultured at 28-35° C. with 200-500 rpm shaking until exponential growth phase, wherein the said seed culture medium by weight percentage comprises the following components:soluble starch 1.0-3.5%, KH2PO4 0.1-0.5%, urea 0.1-0.3%, MgSO4 0.05-0.1%, CaCO3 0.1-0.3%, yeast extract powder 0.1-1.0%, corn syrup 0.1-1.0%, (NH4)2SO4 0.1-0.6% and ferulic acid 0.1-0.3%, andwherein fermentation step 3 comprises:the OMK-4 cells from step 2 in exponential growth phase are inoculated into a fermentation medium with the volume ratio of 5-15% under aseptic conditions wherein the initial pH of the fermentation medium is 7.2 to 7.8 at 30-40° C. and 200-500 rpm shaking and 1:0.5 ventilation, to ferment the cells for 70-120 hours, wherein the fermentation medium by weight percentage comprises the following components: soluble starch 2.0-5.0%, KH2PO4 0.1-0.3%, urea 0.1-0.5%, MgSO4 0.05-0.1%, CaCO3 0.5-2.0%, yeast extract powder 0.1-1.0%, (NH4)2SO4 0.1-0.5% and ferulic acid 0.1-3.0%.
US Pat. No. 10,364,447

PRODUCTION OF OMEGA-3 FATTY ACIDS BY MYXOBACTERIA

Universitat Des Saarlande...

1. A method for the production of omega-3 polyunsaturated fatty acids which comprises:(a) preparing a vegetative inoculum of cells of an Aetherobacter strain that produces one or more omega-3 polyunsaturated fatty acids, wherein the Aetherobacter strain has a 16s rDNA sequence that is at least 97% identical to the 16s rDNA sequence set forth in SEQ ID NO: 1, 2 or 4;
(b) transferring the inoculum of step (a) to an aqueous nutrient medium and culturing the cells of said Aetherobacter strain under submerged aerobic conditions; and
(c) isolating one or more omega-3 polyunsaturated fatty acids from the cells cultured in step (b), wherein isolating comprises the steps of drying the cells, extracting the dried cells and purifying the one or more omega-3 polyunsaturated fatty acids.
US Pat. No. 10,364,455

METHODS AND COMPOSITIONS FOR IMPROVING REMOVAL OF RIBOSOMAL RNA FROM BIOLOGICAL SAMPLES

BIOO Scientific Corporati...

1. A method for removing 28S rRNA from an RNA sample comprising:obtaining an RNA sample from a biological source, said RNA sample containing 28S rRNA;
mixing said RNA sample with one or more RNA subtractive hybridization probes, thereby forming a mixture comprising the RNA sample and the one or more RNA subtractive hybridization probes, wherein the one or more RNA subtractive hybridization probes comprise an affinity label, and wherein the one or more of the RNA subtractive hybridization probes hybridize to two or more discontinuous regions of the 28S rRNA in the RNA sample but do not hybridize to GC rich regions of the 28S rRNA;
incubating the mixture under conditions effective to allow hybridization of the one or more RNA subtractive hybridization probes with the 28S rRNA in the RNA sample, thereby forming a hybridized complex comprising the one or more RNA subtractive hybridization probes and the 28S rRNA;
incubating the hybridized complex with a solid support in a reaction composition containing components that facilitate association of the hybridized complex with the solid support, thereby forming a complex comprising the hybridized complex and the solid support, wherein the affinity label on the one or more RNA subtractive hybridization probes of the hybridized complex specifically binds to an affinity label recognition molecule attached to the solid support; and
removing the 28S rRNA from the RNA sample by removing the complex comprising the hybridized complex and the solid support from the reaction composition.
US Pat. No. 10,362,922

ADSORPTION OF PARTICLES ON A MATERIAL CONTAINING A SILICONE POLYMER

Wacker Chemie AG, Munich...

1. A method for adsorption of particles by triboelectric charging, comprising adsorbing the particles on a material M which comprises an organic polymer material with silicone polymer(s) finely distributed therein, wherein the content of the silicone polymer in the material M is at least 0.0001 wt. % and less than 10 wt. % and wherein said silicon polymer comprises UHMW polysiloxane (ultra-high molecular weight silicone) having a dynamic viscosity from 1 kPa·s to 50 kPa·s at 25° C.
US Pat. No. 10,364,458

ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES

Tangen Biosciences, Inc.,...

1. A two-stage nucleic acid amplification and real-time detection method comprising a providing a composition comprising a target nucleic acid template and at least one primer that anneals to the target nucleic acid template near a region of interest to be amplified; b. performing a first nucleic acid amplification reaction to amplify the region of interest, thereby forming a primary amplicon; c. dividing (b) into at least two secondary reactions, and including in at least one of the reactions a site-specific secondary primer that is complementary to a site-specific primer binding site that may be present within the primary amplicon and defines a site of interest within the region of interest; d. performing a second nucleic acid amplification reaction (second-stage reaction) thereby accelerating the amplification of the region of interest only if the site-specific primer binding site is complementary to the site-specific primer; and e. detecting and comparing in real-time the amplification rates of the at least two secondary reactions, wherein an enhanced relative rate of amplification in the reaction with the secondary primer indicates the presence of the site of interest that is complementary to the secondary primer.
US Pat. No. 10,364,203

METHOD FOR PREPARING PHENOLICS USING A CATALYST

1. Method for preparing a phenolic compound comprising reacting a furanic compound with a dienophile in the presence of a catalyst comprising yttrium.
US Pat. No. 10,364,459

METHOD OF QUANTITATIVELY AND QUALITATIVELY ANALYZING BIOMATERIAL IN REAL-TIME

SUGENTECH, Inc., Daejeon...

1. A method of quantitatively and qualitatively analyzing a biomaterial in real-time, the method comprising:preparing a device for detecting a biomaterial, wherein the device comprises a reaction container comprising an opening at an upper part thereof; and an element part separately connected to the reaction container via the opening, wherein the element part comprises a cap coupled to the opening of the reaction container; and a rod extended from a lower part of the cap, wherein the rod comprises a biochip having a third probe fixed to a surface of the biochip;
feeding a complex of first and second probes, a forward primer, a reverse primer, a sample comprising deoxynucleotide triphosphate (dNTP), a polymerase having exonuclease activity, and a sample comprising target genes, and a reaction solution comprising a buffer into the reaction container, wherein the first probe comprises oligonucleotide sequences complementary to nucleic acid sequences of the target genes in the sample, a first phosphor for generating a first fluorescence signal, and a first quencher for quenching the first phosphor, the second probe does not comprise oligonucleotide sequences complementary to the nucleic acid sequences of the target genes in the sample, but comprises oligonucleotide sequences complementary to the third probe, and the forward and reverse primers comprise oligonucleotide sequences complementary to the nucleic acid sequences of the target genes to amplify the target genes in the sample;
performing polymerase chain reaction comprising denaturation of the target genes in the sample, hybridization of the target genes, the complex, and the forward and reverse primers in the sample, and elongation of the primers through the polymerase having exonuclease activity, wherein the hybridization is only performed between the target genes and the first probe of the complex, and when the polymerase reaches the complex hybridized with the target genes during the elongation by the polymerase having the exonuclease activity, the second probe and the first phosphor are disassembled and released from the complex hybridized with the target genes by the exonuclease activity of the polymerase, and a first fluorescence signal is generated by the first phosphor;
allowing for DNA microarray in which elongation of the second probe on the third probe by the polymerase after hybridizing the released second probe and the third probe fixed to the biochip are performed, wherein the third probe comprises a second phosphor for generating a second fluorescence signal and a second quencher for quenching the second phosphor, and as the second probe is elongated on the third probe, the secondary structure of the third probe is disassembled, and the second quencher is spaced from the second phosphor, and a second fluorescence signal is generated by the second phosphor; and
detecting a first fluorescence signal by the first phosphor and a second fluorescence signal by the second phosphor.
US Pat. No. 10,364,204

PROCESS FOR MANUFACTURING METHYL TERTIARY-BUTYL ETHER (MTBE) AND OTHER HYDROCARBONS

Lyondell Chemical Techno...

1. A process for manufacturing methyl t-butyl ether (MTBE) comprising:a first step comprising cracking raw material comprising ethane or propane to form ethylene; and recovering residual uncracked raw material;
a second step comprising dimerizing ethylene to form a n-butylene feed stream, wherein the n-butylene feed stream comprises:
(i) about 30 to 50 wt. % of 2-butene, based on the total weight of the feed stream,
(ii) about 25 to 45 wt. % of 1-butene, based on the total weight of the feed stream, and
(iii) a higher molecular weight ethylene oligomer
wherein the dimerizing step is performed at a temperature of about 10-100° C., wherein the dimerizing step takes place in the presence of a dimerization catalyst, wherein the dimerization catalyst comprises a nickel compound and an aluminum compound, and wherein the catalyst has a Ni:Al ratio from 0.9:10 to 1:2.5;
a third step comprising isomerizing the n-butylene feed stream to form an isobutylene stream using a isomerization catalyst at a weight hourly space velocity (WHSV) of 0.2-4 kg feedstock per kg catalyst per hour at a pressure of about 345-3450 kPa and a temperature of about 40-200° C., wherein the isomerization catalyst is an acidic isomerization catalyst;
recovering unconverted n-butylene;
alkylating isobutylene with isobutane at a pressure of at least 600 kPa to form gasoline alkylate;
recovering gasoline alkylate;
isomerizing the higher molecular weight ethylene oligomer; and
recovering the isomerized higher molecular weight ethylene oligomer;
a fourth step comprising oxidizing methane to form methanol;
a fifth step comprising etherifying the isobutylene stream with methanol to form methyl t-butyl ether;
etherifying the higher molecular weight ethylene oligomer contained in the isobutylene stream with methanol to form a higher-molecular-weight-ethylene-oligomer-based methyl ether;
recovering the higher-molecular-weight-ethylene-oligomer-based methyl ether;
etherifying an isomerized higher molecular weight ethylene oligomer contained in the isobutylene stream with methanol to form an isomerized-higher-molecular-weight-ethylene-oligomer-based methyl ether; and
recovering the isomerized-higher-molecular-weight-ethylene-oligomer-based methyl ether; and
a sixth step comprising collecting the methyl t-butyl ether.
US Pat. No. 10,364,466

BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS

Genentech, Inc., South S...

1. A method of optimizing therapeutic efficacy of a VEGF antagonist for a patient, the method comprising:(a) detecting expression of at least three genes set forth in Table 2 in a sample obtained from the patient prior to any administration of a VEGF antagonist to the patient;
(b) comparing the expression level of the at least three genes to a reference expression level of the at least three genes, wherein a change in the level of expression of the at least three genes in the patient sample relative to the reference expression level identifies a patient who is likely to respond to treatment with a VEGF antagonist; and
(c) administering a VEGF antagonist to the patient identified in step (b) as likely to respond to treatment with a VEGF antagonist,
wherein the VEGF antagonist is an anti-VEGF antibody and the change in the level of expression of the at least three genes in the patient sample is an increase relative to the reference expression level.
US Pat. No. 10,364,474

MICROBIAL MARKERS AND USES THEREFOR

IMMUNEXPRESS PTY LTD, Bo...

1. A method of treating a sepsis-associated bacterial infection in a mammalian subject, the method comprising:1) determining that a subject has an infection with a sepsis-associated Gram positive or Gram negative bacterium by detecting a single nucleotide polymorphism (SNP) in a 16S rRNA gene in nucleic acid from a blood sample from the subject, wherein the SNP is at a position corresponding to position 396 of the 16S rRNA gene set forth in SEQ ID NO:1, and wherein
the bacterium is determined to be a Gram-negative bacterium only when there is a C at position 396 and the bacterium is determined to be a Gram-positive bacterium only when there is an A, T or G at position 396; wherein the bacterium is selected from among Salmonella enterica, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Enterococcus faecalis, Enterococcus faecium, Clostridium perfringens, Streptococcus anginosus, Streptococcus constellatus, Streptococcus intermedius, Streptococcus mitis, Streptococcus mutans, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus bovis, Streptococcus sanguinis, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus pyogenes, Escherichia coli, Acinetobacter baumannii, Bacteroides fragilis, Burkholderia cepacia, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Citrobacter freundii, Morganella morganii, Haemophilus influenzae, Neisseria meningitidis, Stenotrophomonas maltophila, Prevotella buccae, Prevotella intermedia, Prevotella melaninogenica, Mycobacterium tuberculosis, Streptomyces somaliensis and Streptomyces anulatus; and
2) administering to the subject a therapy when the subject is determined in step 1) to have an infection with a sepsis-associated Gram positive or Gram negative bacterium, wherein the therapy comprises administration of an antibiotic and/or an antibody to endotoxin.
US Pat. No. 10,366,782

METHOD AND SYSTEM FOR MICROBIOME-DERIVED CHARACTERIZATION, DIAGNOSTICS, AND THERAPEUTICS FOR CARDIOVASCULAR DISEASE CONDITIONS

uBiome, Inc., San Franci...

1. A method for at least one of characterizing and treating a cardiovascular condition for a subject, the method comprising:providing a sampling kit to the subject associated with the cardiovascular condition, the sampling kit comprising a sample container and a pre-process reagent component, wherein the sample container is operable to receive a sample;
receiving the sample from the sampling kit, the sample comprising a microorganism component;
selecting a primer set for a nucleic acid sequence set associated with the microorganism component;
with a next generation sequencing platform, determining a set of microorganism nucleic acid sequences based on the sample and the primer set;
generating a microbiome feature dataset for the subject based on the set of microorganism nucleic acid sequences;
generating a characterization of the cardiovascular condition based on the microbiome feature dataset;
determining a therapy for the subject based on the characterization, wherein the therapy is operable to improve a state of the cardiovascular condition; and
providing the therapy to the subject associated with the cardiovascular condition, wherein the therapy is operable to modulate microbiome composition to improve the state of the cardiovascular condition.
US Pat. No. 10,364,478

BAINITE-CONTAINING-TYPE HIGH-STRENGTH HOT-ROLLED STEEL SHEET HAVING EXCELLENT ISOTROPIC WORKABILITY AND MANUFACTURING METHOD THEREOF

NIPPON STEEL CORPORATION,...

1. A bainite-containing high-strength hot-rolled steel sheet, comprising: in mass %,C: greater than 0.07 to 0.2%;
Si: 0.001 to 2.5%:
Mn: 0.01 to 4%;
P: 0.15% or less (not including 0%);
S: 0.03% or less (not including 0%);
N: 0.01% or less (not including 0%);
Al: 0.001 to 2%; and
a balance being composed of Fe and inevitable impurities, wherein an average value of pole densities of the {100}<011> to {223}<110> orientation group represented by respective crystal orientations of {100}<011>, {116}<110>, {114}<110>, {113}<110>, {112}<110>,{335}<110>, and {223}<110> at a sheet thickness center portion being a range of ? to ? in sheet thickness from the surface of the steel sheet is 4.0 or less, and a pole density of the {332}<113>crystal orientation is 4.8 or less, an average crystal grain diameter is 10 ?m or less and a Charpy fracture appearance transition temperature vTrs is ?20° C. or lower, and a microstructure is composed of 35% or less in a structural fraction of pro-eutectoid ferrite and a balance of a low-temperature transformation generating phase.
US Pat. No. 10,363,202

DENTAL MATERIAL INCLUDING PROPYLBARBITURIC ACID POLYMERIZATION CATALYST

SHOFU INC., Kyoto (JP)

1. A dental material comprising a polymerizable monomer, 1-cyclohexyl-5-propylbarbituric acid and trioctylmethylammonium chloride, wherein the polymerizable monomer comprises a (meth)acrylic acid group-containing monomer.
US Pat. No. 10,363,203

METHOD OF USE, AND COMPOSITION OF, FIRST RESPONDER WET WIPES

DIAMOND WIPES INTERNATION...

1. A method for decontaminating a skin surface by use of a wet wipe, wherein the wet wipe has a composition consisting essentially of:water, by wt. %, within a range of 90.00 to 98.00;
propanediol, by wt. %, within a range of 0.10 to 5.00;
a first blend, by wt. %, within a range of 0.001 to 1.00;
a second blend, by wt. %, within a range of 0.10 to 5.00;
polysorbate 20, by wt. %, within a range of 0.10 to 5.00;
a third blend, by wt. %, within a range of 0.001 to 1.00;
trisodium phosphate, by wt. %, within a range of 0.001 to 1.00;
citric acid, by wt. %, within a range of 0.001 to 1.00;
caprylyl glycol, by wt. %, within a range of 0.001 to 1.00;
benzalkonium chloride, by wt. %, within a range of 0.001 to 1.00;
phenoxyethanol, by wt. %, within a range of 0.001 to 1.00;
sodium benzoate, by wt. %, within a range of 0.001 to 1.00; and
potassium sorbate, by wt. %, within a range of 0.001 to 1.00;
wherein the first blend consists of the first group consisting essentially of chamomilla recutita (Matricaria) flower extract, cucumis sativus (cucumber) fruit extract, althaea officinalis root extract and avena sativa (oat) kernel extract;
wherein the second blend consists of the second group consisting essentially of decyl glucoside, polyglyceryl-10 caprylate/caprate, coco glucoside, and glyceryl oleata; and
wherein the third blend consists of tetrasodium glutamate diacetate and sodium hydroxide.
US Pat. No. 10,366,789

METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR NEUROLOGICAL HEALTH ISSUES

uBiome, Inc., San Franci...

1. A method for characterizing a pernicious anemia condition for a subject, the method comprising:for each sample of an aggregate set of samples comprising at least one sample comprising microorganisms associated with the pernicious anemia condition:
determining a microorganism nucleic acid sequence upon fragmenting nucleic acid material from the sample, and amplifying the fragmented nucleic acid material using a primer; and
determining an alignment of the microorganism nucleic acid sequence to a reference nucleic acid sequence, thereby determining alignments;
generating a microbiome feature dataset based on the alignments;
generating a characterization of the pernicious anemia condition based on the microbiome feature dataset;
determining a therapy for the subject based on the characterization and a subject sample from the subject; and
providing the therapy to the subject, wherein the therapy is operable to modulate microbiome composition to improve a state of the pernicious anemia condition.
US Pat. No. 10,363,207

ALL-IN-ONE SKIN-BRIGHTENING FORMULATIONS

1. An all-in-one skin treatment formulation comprising a base composition of ingredients of:from 91.78 to 96% by weight of water;
from 0.0001 to 2% by weight of Kojic Acid;
from 0.05 to 0.15% by weight of Niacinamide;
from 0.8 to 1.2% by weight of Sodium Hyaluronate;
from 0.008 to 0.012% by weight of Licorice Extract; and
from 0.08 to 0.12% by weight of Tocopherol;
up to 5% by weight of a biomimetic encapsulated whitening peptide, wherein said biomimetic encapsulated whitening peptide component comprises water, butylene glycol, hydrogenated lecithin, sodium oleate, oligopeptide-68, and sodium ethylene diamine-tetraacetic acid (EDTA);
up to 0.01% by weight of Retinol;
from 0 to 1.1% by weight of preservatives;
from 0 to 2.5% of lactic acid;
from 0 to 2.5% of glycolic acid; and
from 0 to 2% by weight of Hydroquinone; wherein said biomimetic encapsulated whitening peptide and said Retinol are both present.
US Pat. No. 10,363,719

MONOAXIALLY ORIENTED MULTILAYER CAST FILM

Borealis AG, Vienna (AT)...

1. A multilayer cast film oriented in machine direction, the multilayer cast film comprises at least three layers A, B and C, whereina) layer A is an outer layer comprising a heterophasic propylene copolymer, wherein the heterophasic propylene copolymer of layer A comprises
a-a) 75 to 95 wt % of a polypropylene matrix (PP-M) with an MFR2 (ISO 1133, 230° C., 2.16 kg) of 0.5 to 30.0 g/10 min being a homopolymer or a copolymer which has a comonomer content of less than 10.0 wt %,
a-b) 5 to 25 wt % of a propylene/alpha-olefin rubber (EPR) with at least 50 wt % propylene having an intrinsic viscosity (IV) of 0.8 to 2.5 dl/g, and
a-c) 0.0001 to 1 wt % of an alpha-nucleating agent (NA);
b) layer B is a core layer comprising a high isotacticity polypropylene homopolymer, wherein the high isotacticity polypropylene homopolymer of layer B is characterized by
(b-i) an isotacticity expressed in mmmm pentads of at least 96 mol %, measured by means of 13 C-NMR,
(b-ii) a decaline soluble content of 2.0 wt % or below, and
(b-iii) polydispersity index (PI) of at least 5.5;
and
c) layer C is a sealing layer comprising a propylene based random copolymer or a propylene based terpolymer, optionally in combination with a heterophasic propylene copolymer, wherein the propylene based random copolymer or terpolymer of layer C comprises
(c-i) 80.0 to 98.0 wt % of propylene,
(c-ii) up to 5.0 wt % of ethylene, and
(c-iii) 1.5 to 20.0 wt % of an alpha-olefin having 4 to 20 carbon atoms,
wherein the sum of (c-i), (c-ii), (c-iii) is 100 wt % and the amount of ethylene (c-ii), if present, is lower than the amount of alpha-olefin (c-iii),
wherein the machine direction oriented multilayer cast film has
(i) a tensile modulus measured according to ISO 527-3 on a 50 ?m film in machine direction of at least 2600 MPa and in transverse direction of at least 1200 MPa,
(ii) a haze value measured according to ASTM D1003 on a 50 ?m film of at most 5.5%, and
(iii) a shrinkage measured according to the method as described in the experimental parton a 50 ?m film after 10 minutes at 100° C. in machine direction of at most ?3.0%.
US Pat. No. 10,364,231

METHOD FOR PRODUCING 2,3,5-TRIMETHYL BENZOQUINONE BY OXIDATION OF 2,3,6-TRIMETHYLPHENOL

BASF SE, (DE)

1. A mixture consisting essentially of 2,3,5-trimethylbenzoquinone, the mixture being prepared by a process consisting essentially of the following step:(i) oxidizing 2,3,6-trimethylphenol to 2,3,5-trimethylbenzoquinone with oxygen or an oxygen-containing gas in a two-phase or multiphase reaction medium in the presence of a catalyst or catalyst system at least comprising a copper(II) halide, to give a mixture comprising 2,3,5-trimethylbenzoquinone,wherein the reaction medium comprises water and at least one secondary aliphatic acyclic alcohol having 6 or more carbon atoms.
US Pat. No. 10,363,211

HAIR CONDITIONING COMPOSITIONS COMPRISING LOW VISCOSITY EMULSIFIED SILICONE POLYMERS

The Procter and Gamble Co...

1. A hair conditioning composition comprising:a) a silicone polymer comprising:
i. one or more quaternary groups;
ii. at least one silicone block comprising greater than 200 siloxane units;
iii. at least one polyalkylene oxide structural unit; and
iv. at least one terminal ester group;
wherein said silicone polymer has a viscosity of 500 mPa·s to 100,000 mPa·s at 20° C. at 100% concentration of said silicone polymer with no additional solvents and a shear rate of 0.1 s?1,
wherein said silicone polymer is added to create a pre-emulsified dispersion with a particle size of less than about 1 micron, and
b) a gel matrix comprising:
i. a cationic surfactant;
ii. a high melting point fatty compound, wherein the high melting point fatty compound has a melting point of about 25° C. or higher; and
iii. an aqueous carrier;
wherein said silicone polymer is mixed with said gel matrix.
US Pat. No. 10,363,212

AESCULUS HIPPOCASTANUM EXTRACT

1. A method of improving an appearance of a skin and/or a mucosa, to improve cutaneous strength and/or elasticity, to treat or prevent skin aging, wrinkles, or skin slackening, the method comprising:administering an extract for a cosmetic treatment of the skin and/or mucosa,
said extract being an Aesculus hippocastanum extract obtained by an extraction method comprising:
a solid/liquid extraction step of a flower of Aesculus hippocastanum with a solvent, followed by
a second solid/liquid separation step, and
a third step for recovering the liquid phase,
wherein the solvent consists of a mixture of fructose and glycerin and water.
US Pat. No. 10,365,262

METHOD OF MONITORING A PARAMETER OF A HYDROCARBON WELL, PIPELINE OR FORMATION

Johnson Matthey Public Li...

1. A method of monitoring a parameter of a hydrocarbon well, pipeline or formation, the method comprising:introducing a tracer into the hydrocarbon well, pipeline or formation;
producing a fluid from the hydrocarbon well, pipeline or formation; and
analysing the fluid to determine if the tracer is present in the fluid;
wherein the tracer comprises a halogenated alkoxylated-benzoic acid, an alkoxylated benzene sulfonic acid, a salt of a halogenated alkoxylated-benzoic acid, or a salt of an alkoxylated benzene sulfonic acid.
US Pat. No. 10,366,799

TRANSPARENT CONDUCTOR, METHOD FOR PREPARING THE SAME AND DISPLAY APPARATUS INCLUDING THE SAME

SAMSUNG SDI CO., LTD., Y...

1. A transparent conductor, comprising:metal nanowires; and
a matrix in which the metal nanowires are embedded,
wherein:
a capping layer is formed on surfaces of the metal nanowires, the capping layer including a sulfur-containing compound, and
the capping layer has a thickness of about 0.025 or less times an average diameter of the metal nanowires.
US Pat. No. 10,363,217

NANO-LIPOSOME CARRIER COMPOSITION CONTAINING HYBRID OF CAS9 PROTEIN AND GUIDE RNA

Moogene Medi Co., Ltd., ...

19. A method for producing a nano-liposome carrier composition, the method comprising:mixing a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein 9 (Cas9) protein and a guide RNA that specifically binds to a target DNA of a human dipeptidyl peptidase-4 (DPP4) gene to produce a hybrid CRISPR complex;
mixing a lecithin, a metal chelating lipid, and a cholesterol in chloroform to produce a lipid film composition;
mixing the hybrid CRISPR complex with the lipid film composition to produce a lipid/CRISPR mixture and applying ultrasonic waves to the lipid/CRISPR mixture;
freezing and thawing the lipid/CRISPR mixture;
re-applying ultrasonic waves to the lipid/CRISPR mixture for a time sufficient to form nano-liposomes encapsulating the hybrid CRISPR complex; and
centrifuging the lipid/CRISPR mixture for a time sufficient to precipitate nano-liposomes encapsulating the hybrid CRISPR complex; and
collecting precipitated nano-liposomes encapsulating the hybrid CRISPR complex.
US Pat. No. 10,363,218

SYNTHESIS OF PROBIOTIC NANOPARTICLES

King Saud University, Ri...

1. An method of fabricating a probiotic nanoparticle, comprising:(a) dissolving a probiotic in methanol to form a first solution;
(b) spraying the first solution into boiling water at a controlled flow rate under ultrasonic conditions to form a sonicated solution; and
(c) stirring the sonicated solution to provide the probiotic nanoparticle.
US Pat. No. 10,364,242

MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT

FONDAZIONE ISTITUTO ITALI...

1. The compound (endo)-3-(4-butylphenoxy)-8-[(3,5-dimethyl-1H-pyrazol-4-yl)sulphonyl]-8-azabicyclo[3.2.1]octane, pharmaceutically acceptable salts thereof, its hydrates, solvates and racemic mixtures.
US Pat. No. 10,363,221

MANUFACTURING SOLID PHARMACEUTICAL DOSAGE FORMS WITH VISIBLE MICRO- AND NANOSTRUCTURED SURFACES AND MICRO- AND NANOSTRUCTURED PHARMACEUTICAL DOSAGE FORM

I-Property Holding Corp.,...

1. A method of forming a pharmaceutical dosage form comprising:impressing, on at least one of a surface and an interface of the dosage form, an area with at least one micro- and/or nanostructure;
the dosage form comprising a quantity and distribution of ingredients so as to enhance an optical contrast effect caused by the impressed micro and/or nanostructure, so that the micro- and/or nanostructure is observable by the human eye,
wherein the impressing is defined by only direct compression of a mixture of selected ingredients with a punching tool to create the solid pharmaceutical dosage form, with the direct compression performed at room temperature without heating and without modifying the physical nature of the material in the mixture, the punching tool having a micro and/or nano-structured surface formed in a tool surface geometry, and wherein particles of the mixture of selected ingredients are sized such that at least some of the particles are reconfigured or deformed by the compressing, these particles thereby taking the shape of the micro and/or nano-structured surface of the punching tool.
US Pat. No. 10,364,246

SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES

Janssen Pharmaceutica NV,...

1. A compound selected from the group consisting of2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-(2-hydroxy-2-methylpropyl)acetamide;
2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile;
2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-((1-hydroxycyclopropyl)methyl)acetamide; and
pharmaceutically acceptable salts, and combinations thereof.
US Pat. No. 10,363,223

DELAYED-RELEASE ENCAPSULATION OF DEER VELVET POWDER TO PROTECT THE DEER VELVET POWDER UNTIL MICELLIZATION AND ABSORPTION WITHIN THE TERMINAL ILLIUM

1. A capsule of deer velvet powder for ensuring delivery of unaltered molecules of the deer velvet powder systemically to organs of a body, the body having a stomach and a small intestine, the small intestine having a terminal ileum, the capsule of deer velvet powder comprising:a delayed release capsule; and
a quantity of deer velvet powder contained within the delayed release capsule,
the delayed release capsule made using hydroxypropyl methylcellulose, and
the delayed release capsule configured to resist digestive processes in the stomach so as to release the quantity of deer velvet powder substantially along the small intestine, thereby ensuring micellization and absorption of various components of the deer velvet powder along the terminal ileum.
US Pat. No. 10,363,224

EXTENDED-RELEASE TOPIRAMATE CAPSULES

UPSHER-SMITH LABORATORIES...

1. A method of dosing a subject for the treatment of convulsions, the method comprising:administering an extended-release topiramate capsule once daily to the subject, wherein the extended-release topiramate capsule comprises:
a capsule shell comprising a single population of coated particles;
wherein each coated particle comprises a core and a coating thereon;
wherein each particle core comprises a homogeneous mixture comprising topiramate throughout its core; and
wherein the coating comprises one or more release controlling agent(s);
wherein the extended-release topiramate capsule, when given as a single-dose to a healthy human subject, achieves an AUC0-inf of 170 to 210 h??g/mL within a 95% confidence interval, and a Cmax of 2 to 4 ?g/mL within a 95% confidence interval.
US Pat. No. 10,365,272

HIGHLY SENSITIVE IMMUNOASSAY FOR RAPID QUANTIFICATION OF MENINGOCOCCAL CAPSULAR POLYSACCHARIDE ANTIGENS

SERUM INSTITUTE OF INDIA ...

1. A method for quantification of conjugated N. meningitidis serogroup X capsular polysaccharide in a sample using an immunological assay, the method comprising:providing a solid support coated with a capture polyclonal antibody;
providing a sample including N. meningitidis serogroup X capsular polysaccharide-TT conjugate and unconjugated N. meningtitidis serogroup X capsular polysaccharide, wherein the sample is lyophilized and resuspended in phosphate buffer saline having pH 7.2±0.2 comprising KCl at a concentration from 75 mM to 140 mM followed by further dilution or the sample is liquid and directly diluted with phosphate buffer saline having pH 7.2±0.2 comprising KCl at a concentration from 75 mM to 140 mM;
applying the sample to the solid support coated with capture polyclonal antibody;
removing unbound sample;
providing a detection monoclonal antibody;
applying the detection monoclonal antibody to the solid support;
removing unbound detection monoclonal antibody;
applying labeled secondary antibody with a label; and
detecting the label;
wherein the assay does not show any interference due to presence of sucrose and glucose excipients.
US Pat. No. 10,364,251

POLYESTERS FROM ASSYMETRICAL MONOMERS BASED UPON BISANHYDROHEXITOLS

New Jersey Institute of T...

1. An AB monomer comprising bisanhydrohexitol derivatives capable of self-polymerization directly to form a sterioregular or regioregular condensation polymer, wherein the AB monomer has the structure:A—X—C—Y—B
wherein:
a. A is a carboxylic acid, an ester, or an acid chloride,
b. Y is a bisanhydrohexitol unit derived from isosorbide, isoidide or isomannide;
c. X is selected from the group consisting of:
i. aromatic rings, including 1,4-phenylene, 1,3-phenylene, 2,6-naphthalene, 2,7-naphthalene or substituted derivatives thereof;
ii. substituted or unsubstituted heterocycles, and
iii. saturated or unsaturated aliphatic chains;
d. B is —OH; and
e. C is an ester carbonyl link with the carbon attached to X and the oxygen attached to Y, and wherein the AB monomer is at least about 98% pure endo-substituted bisanhydrohexitol derivative or an at least about 98% pure exo-substituted bisanhydrohexitol derivative.
US Pat. No. 10,365,277

METHOD FOR MEASURING HEMAGGLUTININ FROM INFLUENZA VIRUS

DENKA SEIKEN CO., LTD., ...

1. A method for measuring haemagglutinin of an influenza virus by a sandwich immunoassay method, said method comprising:extracting haemagglutinin from a sample containing the influenza virus by adding a cationic or anionic surfactant;
combining the extracted haemagglutinin with at least one lectin immobilized on a solid support and with a labeled anti-haemagglutinin antibody that undergoes antigen-antibody reaction with the haemagglutinin; and
measuring the haemagglutinin by sandwich immunoassay, wherein detection of the presence of haemagglutinin indicates the presence of influenza virus,
wherein the at least one lectin binds the haemagglutinin, but does not bind the anti-haemagglutinin antibody, and wherein the at least one lectin is Datura stramonium lectin, and
wherein the cationic and anionic surfactant is at least one selected from the group consisting of sodium dodecyl sulfate, lithium dodecyl sulfate, hexadecyltrimethylammonium bromide, hecadecyltrimethylammonium chloride and hexadecylpyridinium chloride.
US Pat. No. 10,363,232

COMPOSITIONS AND METHODS FOR TREATING SEVERE PAIN

Infirst Healthcare Limite...

1. A method of treating an individual with an inflammatory pain, the method comprising the step of: administering to the individual in need thereof a pharmaceutical composition, wherein the pharmaceutical composition comprises:a) a propionic acid derivative non-steroidal anti-pain drug (NSAID), or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof, in an amount of about 15% to about 30% of the total weight of the composition; and
b) a pharmaceutically-acceptable lipid in an amount of at least 50% of the total weight of the composition, the pharmaceutically-acceptable lipid comprising a pharmaceutically-acceptable triglyceride in an amount of at least 30% of the total weight of the composition, and a pharmaceutically-acceptable glyceride mixture including a monoglyceride, the pharmaceutically-acceptable glyceride mixture in an amount of at least 20% of the total weight of the composition,
wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature of about 25° C. or higher.
US Pat. No. 10,364,512

MULTIFILAMENT AND BRAID

TOYOBO CO., LTD., Osaka-...

10. A braid comprising a multifilament comprising 5 or more monofilaments, whereinthe braid shows 1000 times or more in number of reciprocating abrasions at break in an abrasion resistance test measured at a load of 5 cN/dtex in accordance with JIS L-1095, and
the multifilament contains polyethylene having an intrinsic viscosity [?] of 5.0 dL/g or more and 40.0 dL/g or less and substantially including ethylene as a repeating unit.
US Pat. No. 10,365,280

COMPOSITIONS AND METHODS FOR TREATING MALIGNANCIES

DANA-FARBER CANCER INSTIT...

1. A method for identifying a therapeutic agent for treating multiple myeloma (MM), the method comprising:(a) providing a first polypeptide comprising a CD147 polypeptide and a second polypeptide comprising an extracellular cyclophilin A (eCyPA) polypeptide sequence under conditions that allow for binding of the CD147 polypeptide and the eCyPA sequence;
(b) contacting the complex with a test agent;
(c) determining whether the test agent disrupts binding of the first and second polypeptide,wherein disruption of the binding of the first polypeptide and second polypeptide by the test agent indicates the test agent is a putative therapeutic agent for treating MM;(d) contacting the putative therapeutic agent with a multiple myeloma (MM) cell population expressing CD147; and
(e) determining whether the putative therapeutic agent inhibits migration of MM cells from the MM cell population into bone marrow,
wherein inhibition of MM cell migration indicates the test agent is a therapeutic agent for treating MM.
US Pat. No. 10,363,233

GRANULAR FEED SUPPLEMENT

14. A method of supplementing the diet of a ruminant with lysine, the method comprising:providing the ruminant with a ruminant feed composition comprising:
a granulated core comprising lysine sulfate; and
a coating material of two or more layers surrounding the core, the coating material comprising;
oleic acid,
stearic acid, and
palmitic acid;
wherein the total amount of stearic and palmitic acids is at least 90 wt % of the total weight of the coating,
wherein the lysine exhibits a rumen bypass rate greater than 75%, and an intestinal digestibility rate greater than 70%, and
wherein the weight % ratio of core material to coating material is from 50:50 to 70:30.
US Pat. No. 10,365,281

BIOMARKERS OF RAPID PROGRESSION IN ADVANCED NON-SMALL CELL LUNG CANCER

Rush University Medical C...

1. A method for measuring a panel of biomarkers in a subject suspected of having rapidly progressing lung cancer the method comprising:obtaining a biological sample from the subject;
determining whether the subject is treatment naïve or has received at least one treatment;
assaying a level of each biomarker in a first biomarker panel or a second biomarker panel in the biological sample, the first biomarker panel comprising sTNFRI, sTNFRII, CA 19-9, Follistatin, Total PSA, TNF-? and IL-6 for treatment naïve subjects and the second biomarker panel comprising TRAIL, sTNFRI, IGFBP-1, sEGFR, IGF-1, TGF-?, HGF, MMP-7, MMP-2, ?-fetoprotein, Osteopontin, sVEGFR2 and IL-6 for subjects having received at least one treatment.
US Pat. No. 10,364,514

FLUOROPOLYMER FIBRE

SOLVAY SA, Brussels (BE)...

1. A process for manufacturing one or more fluoropolymer fibres, said process comprising:contacting a liquid composition (C1) comprising:
at least one fluoropolymer comprising at least one hydroxyl end group [polymer (FOH)], and
a liquid medium comprising at least one organic solvent (S);with at least one metal compound (M) of formula (I):X4?mAYm  (I)
wherein X is a hydrocarbon group, optionally comprising one or more functional groups, m is an integer from 1 to 4, A is a metal selected from the group consisting of Si, Ti and Zr, and Y is a hydrolysable group selected from the group consisting of an alkoxy group, an acyloxy group and a hydroxyl group, thereby providing a liquid composition (C2);
submitting composition (C2) to at least partial hydrolysis and/or polycondensation, thereby providing a liquid composition (C3) comprising at least one fluoropolymer hybrid organic/inorganic composite;
processing composition (C3) by electrospinning, thereby providing one or more fluoropolymer fibres;
drying the fluoropolymer fibre(s), thereby providing one or more dried fluoropolymer fibres; and
optionally, submitting to compression the dried fluoropolymer fibre(s) at a temperature comprised between 50° C. and 300° C., thereby providing compressed fluoropolymer fibres.
US Pat. No. 10,365,282

METHOD AND BIOMARKER FOR DETECTING METASTASIS OF SARCOMA

SHANGHAI KEXIN BIOTECH CO...

1. A method for diagnosing a subject suspect of having sarcoma metastasis, the method comprising:obtaining a biological sample of the subject, wherein the biological sample is serum or plasma;
detecting a level of a N-terminal segment of moesin in the biological sample;
comparing the level of the N-terminal segment of moesin detected in the biological sample of the subject to a reference level of the N-terminal segment of moesin detected from a reference sample; and
administering to the subject a treatment for metastasis of a sarcoma when the level of the N-terminal segment of moesin detected in the biological sample is higher than the reference level.
US Pat. No. 10,363,235

COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING SAME

Afimmune Limited, (IE)

1. A method of reducing or preventing fibrosis in a subject in need thereof, the method comprising;identifying the subject as having or as having an increased risk for developing fibrosis associated with an organ or tissue selected from the group consisting of: liver, heart, mediastinum, bone marrow, retroperitoneaum, skin, intestine, joint, and a reproductive organ, or a combination thereof; and, based on the identification,
administering to the subject a composition comprising 15-HEPE wherein the 15-HEPE represents at least 80% by weight of all fatty acids in the pharmaceutical composition.
US Pat. No. 10,364,515

HIGH MODULUS NYLON 6.6 CORDS

KORDSA TEKNIK TEKSTIL ANO...

1. A two or three-ply dipped and heat-set polyamide 6.6 cord comprising: a plurality of polyamide 6.6 raw yarns;wherein the plurality of polyamide 6.6 raw yarns have a tensile stress value greater than 1.30 cN/dtex;
wherein a stress value at 4% elongation of the polyamide 6.6 cord is higher than 1.2 cN/dtex and less than 2.0 cN/dtex,
wherein a heat shrinkage of the polyamide 6.6 cord is higher than 4.0% and less than 7.0% determined at 177° C. under 0.045 g/dtex pretension with 2 minutes exposure time;
wherein the tensile stress value is determined with a tensile tester according to ASTM D885-16.
US Pat. No. 10,365,283

ACTIVATED HER3 AS A MARKER FOR PREDICTING THERAPEUTIC EFFICACY

Daiichi Sankyo Europe Gmb...

1. A method for treating patients responsive to a target specific therapy comprising an inhibitory anti-HER3 antibody, comprising(a) obtaining at least one sample from a subject having a tumor disease, prior to treatment with an inhibitory anti-HER3 antibody, wherein the sample is a normal hair follicle biopsy,
(b) obtaining at least one sample from said subject having said tumor disease after treatment with the inhibitory anti-HER3 antibody, wherein the sample is a normal hair follicle biopsy,
(c) examining the phosphorylation level of a HER3 receptor in said samples,
(d) determining that the phosphorylation level of the HER3 receptor is reduced after treatment with the inhibitory anti-HER3 antibody as compared to the phosphorylation level of the HER3 receptor before treatment with the inhibitory anti-HER3 antibody, and
(e) administering to the subject with said tumor disease, who has been determined in step (d) to have a reduced phosphorylation level of the HER3 receptor, a therapeutically effective amount of said inhibitory anti-HER3 antibody,
wherein the tumor disease is selected from the group consisting of NSCLC, breast, colon, gastric, pancreas and prostate cancer, and
wherein said inhibitory anti-HER3 antibody is selected from the group consisting of antibody U3-1287, 105.5, SGP-1, H3 90.6, 1B4C3, and 2D1 D12.
US Pat. No. 10,363,236

ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE

The William M. Yarbrough ...

1. A surfactant formulation, comprising:a lysine derivative, wherein the lysine derivative comprises an ?-nitrogen and a ?-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least 8 carbon atoms is bound to the ?-nitrogen, and further wherein the ?-nitrogen forms part of an isothiocyanate functional group.
US Pat. No. 10,364,260

PROCESS FOR PREPARING TRIS[3-(ALKOXYSILYL)PROPYL] ISOCYANURATES

Evonik Degussa GmbH, Ess...

1. A process for preparing at least one tris[3-(alkoxysilyl)propyl] isocyanurate selected from the group consisting of tris[3-(trialkoxysilyl)propyl] isocyanurate, tris[3-(alkyldialkoxysilyl)propyl] isocyanurate and tris[3-(dialkylalkoxysilyl)propyl] isocyanurate by hydrosilylation, the process comprising:(A) initially charging a mixture comprising at least one H-silane selected from the group consisting of hydrotrialkoxysilane, hydroalkyldialkoxysilane, and hydrodialkylalkoxysilane, with at least one carboxylic acid and a Pt catalyst, and heating the mixture to a temperature of 50 to 140° C.,
(B) adding a mixture of 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione and at least one alcohol to the mixture obtained in (A) while mixing,
(C) leaving the mixture obtained in (B) to react while mixing and
(D) working up the product mixture thus obtained.
US Pat. No. 10,364,262

METHOD FOR THE SYNTHESIS OF N-PHOSPHONOMETHYLIMINODIACETIC ACID

Monsanto Technology LLC, ...

1. A method for synthesis of N-phosphonomethyliminodiacetic acid or derivatives thereof selected from the group consisting of phosphonate esters of N-phosphonomethyliminodiacetic acid, carboxylate esters of N-phosphonomethyliminodiacetic acid, phosphonate and carboxylate esters of N-phosphonomethyliminodiacetic acid, N-phosphonomethyliminodiacetic acid salts, phosphonate esters of N-phosphonomethyliminodiacetic acid salts, carboxylate esters of N-phosphonomethyliminodiacetic acid salts and phosphonate-carboxylate esters of N-phosphonomethyliminodiacetic acid salts, wherein a cation of the salt is selected from the group consisting of ammonium, isopropylammonium, ethanolammonium, dimethylammonium, trimethylsulfonium, sodium and potassium,comprising the steps of:
a) forming an anhydrous reaction mixture comprising an acid catalyst, a compound of the following general formula R1—CH2—NX—CH2—R2 and a compound having one or more P—O—P anhydride moieties, to form a compound having the general formula R1—CH2—N(—CH2PO3R32)(—CH2—R2), wherein in the compound of the formula R1—CH2—NX—CH2—R2:
X is —CH2—COOH and R1 and R2 are each independently nitrile or C1-C4 alkyl carboxylate, or R1 and R2 are both carbonyl groups linked by means of a hydrogen substituted nitrogen atom or a C1-C4-alkyl substituted nitrogen atom; or
X is —CH2—OH and R1 and R2 are each independently nitrile, C1-C4 carboxylate, or carboxylic acid, or R1 and R2 are both carbonyl groups linked by means of a hydrogen substituted nitrogen atom or a C1-C4-alkyl substituted nitrogen atom;
and wherein in the compound having the general formula R1—CH2—N(—CH2PO3R32)(—CH2—R2), R3 is H, an alkyl group; and
the P—O—P anhydride moieties comprising compound is a compound wherein at least one of the one or more P—O—P anhydride moieties comprises one P atom at the oxidation state (+III) and one P atom at the oxidation state (+III) or (+V) and is selected from the group consisting of tetraphosphorus hexaoxide, P4O7, P4O8, P4O9, pyrophosphites of general formula (RO)2P—O—P(OR)2 wherein R is an alkyl or aryl group, and combinations thereof, and
b) hydrolyzing the compound having the general formula R1—CH2—N(—CH2PO3R32)(—CH2—R2) to form N-phosphonomethyliminodiacetic acid or one of its derivatives.
US Pat. No. 10,365,288

CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION

THE JOHNS HOPKINS UNIVERS...

1. A method for detecting citrullinated brain injury biomarker proteins in a sample from a subject having or suspected of having brain injury, the method comprising:detecting in the subject's sample citrullinated arginine residues in citrullinated brain injury biomarker protein glial fibrillary acidic protein (GFAP) and/or citrullinated brain injury biomarker protein myelin basic protein (MBP) by detecting the citrullinated arginine residues in said citrullinated biomarker proteins using a detection method selected from mass spectrometry, immunoassay, electrochemical luminescent assay, electrochemical voltametry, electrochemical amperometry, atomic force microscopy, radio frequency multipolar resonance spectroscopy, confocal microscopy, non-confocal microscopy, fluorescence optical detection, luminescence optical detection, chemiluminescence optical detection, absorbance optical detection, reflectance optical detection, transmittance optical detection, birefringence optical detection, refractive index detection, surface plasmon resonance, ellipsometry, resonant mirror detection, grating coupler waveguide detection, or interferometry; thereby detecting citrullinated brain injury biomarker proteins in the subject's sample.
US Pat. No. 10,363,242

METHODS OF INHIBITING CATARACTS AND PRESBYOPIA

UNIVERSITY OF MASSACHUSET...

1. An ophthalmic composition comprisingat least one ?-crystallin charge masking agent, wherein the at least one ?-crystallin charge masking agent is a bifunctional molecule consisting of
two different end groups selected from NH2, methyl, a succinimide, a carboxylic acid, isocyanate, an isothiocyanate, a sulfonyl chloride, an aldehyde, a carbodiimide, an acyl azide, an anhydride, a fluorobenzene, a carbonate, an N-hydroxysuccinimide ester, an imidoester, an epoxide and a fluorophenyl ester,
covalently linked to a molecular bristle that is a polyethylene glycol having 4 to 200 oxyethylene groups, an alkoxy-polyethylene glycol having 4 to 200 alkoxyethylene groups, an aryloxypolyethylene glycol having 4 to 200 aryloxyethylene groups, poly(2-hydroxypropyl)methacrylamide (HPMA), poly(2-hydroxyethyl)methacrylate (HEMA), a poly(2-oxaziline), poly(m-phosphocholine, poly lysine, or poly glutamic acid, the molecular bristle having a number average molecular weight of 150 to 8000, and
an ophthalmically acceptable excipient.
US Pat. No. 10,364,268

ION EXCHANGE MEMBRANE CHROMATOGRAPHY

Genentech, Inc., South S...

1. A method of enhancing efficiency of downstream chromatography steps for purification of antibodies consisting of:a. passing a harvested cell culture fluid composition comprising an antibody of interest and various contaminants through a cation exchange membrane, wherein the antibody and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH of about 1 to about 5 pH units below the pl of the antibody and a conductivity of ?about 40 mS/cm, which cause the membrane to bind the antibody and at least one ionic polymer contaminant, where in the ionic polymer contaminant is one or more of polyethyleneimine (PEI), polyvinylamine, polyarginine, polyvinylsulfonic acid, or polyacrylic acid;
b. overloading the cation exchange membrane to promote competitive adsorption such that at least one ionic polymer contaminant remains bound to the membrane while the antibody of interest is primarily in the effluent;
c. collecting the effluent from the cation exchange membrane comprising the antibody of interest;
d. subjecting the membrane effluent comprising the antibody of interest to a cation exchange chromatography purification step, wherein the dynamic binding capacity of the cation exchange chromatography purification step is significantly improved as a result of steps (a) through (c);
e. recovering the purified antibody from the effluent of the cation exchange chromatography purification step;
f. subjecting the cation exchange chromatography purified pool to a final polishing step; and
g. recovering the purified antibody of interest.
US Pat. No. 10,363,246

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

Ovid Therapeutics Inc., ...

1. A method of treating essential tremor comprising administering to a patient in need thereof a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,364,274

EXPRESSION OF CHIMERIC KSAC PROTEIN AND METHOD OF PRODUCING SOLUBLE PROTEINS BY HIGH PRESSURE

BOEHRINGER INGELHEIM ANIM...

1. A composition comprising (i) a refolded and solubilized fusion protein and (ii) dithiothreitol (DTT), wherein the fusion protein consists of leishmania antigens Kinetoplastid Membrane Protein 11 (KMP11), Sterol MethylTransferase (SMT), A2 and Cysteine Proteinase (CP), and wherein the fusion protein comprises the sequence as set forth in SEQ ID NO:2.
US Pat. No. 10,364,276

PEPTIDE FOR INDUCING REGENERATION OF TISSUE AND USE THEREOF

STEMRIM INC., Osaka (JP)...

1. A method of stimulating migration of a cell, mobilizing a cell from bone marrow to peripheral blood, and/or regenerating a tissue, in the body of a subject, wherein said method comprises administering to the subject an effective amount of a substance of any one of (a) to (c) below;(a) a peptide consisting of a portion of an HMGB1 protein of SEQ ID NO:1 and having cell migration-stimulating activity;
(b) a cell secreting said peptide of (a); and
(c) a vector into which a DNA encoding said peptide of (a) is inserted, wherein said peptide has an activity of stimulating migration of a cell and said peptide consists of all or part of the amino acid sequence of positions 1 to 195 of SEQ ID NO:1.
US Pat. No. 10,363,253

COMBINATION PRODUCTS FOR THE TREATMENT OF RSV

Janssen Sciences Ireland ...

1. A combination comprising 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl-(methyl)-1-(2,2,2-trifluoroethyl)-1.3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, or a pharmaceutically acceptable salt thereof, as Compound A, and one or more Compound B selected from ribavirin, GS-5806, MDT-637, A-60444, AZ-27, CR9501, palivizumab, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)nicotinamido)-benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-3H-imidazo[4,5h]isoquinoline-7,9(6H, 8H)-dione.
US Pat. No. 10,364,277

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

NEWSOUTH INNOVATIONS PTY ...

1. A method for detecting the presence or absence of an immune cell or antibody in a subject comprising:contacting a biological sample obtained from the subject with a polypeptide, wherein the polypeptide consists of
SEQ ID NO: 2 (KRFNALQYL) or SEQ ID NO: 3 (KRFNALQCL); and
detecting the presence or absence of a binding interaction between the polypeptide and an immune cell or antibody in said sample.
US Pat. No. 10,362,742

MELON PLANTS WITH WHITEFLY RESISTANCE

NUNHEMS B.V., Nunhem (NL...

1. A non-wild, cultivated Cucumis melo plant, or part thereof, comprising resistance against whitefly, wherein said resistance is conferred by an introgression fragment on chromosome 11 in homozygous or heterozygous form and wherein said introgression fragment is from a wild plant of the species Cucumis melo, a representative sample of seeds has been deposited under accession number NCIMB 41965 and NCIMB 41966, and wherein said introgression fragment comprises at least one of the following Single Nucleotide Polymorphism (SNP) markers:a) the CC genotype or CT genotype for the SNP marker mME20364 in SEQ ID NO: 1;
b) the AA genotype or AG genotype for the SNP marker mME17490 in SEQ ID NO: 2;
c) the CC genotype or CT genotype for the SNP marker mME15248 in SEQ ID NO: 3;
d) the CC genotype or CT genotype for SNP marker mME17306 in SEQ ID NO: 4;
e) the AA genotype or AT genotype for SNP marker mME26059 in SEQ ID NO: 5;
f) the GG genotype or GA genotype for SNP marker mME38084 in SEQ ID NO: 6;
g) the CC genotype or AC genotype for SNP marker mME21974 in SEQ ID NO: 7;
h) the CC genotype or CT genotype for SNP marker mME12777 in SEQ ID NO: 8;
i) the GG genotype or GA genotype for SNP marker mME15151 in SEQ ID NO: 9;
j) the CC genotype or CA genotype for SNP marker mME26139 in SEQ ID NO: 10;
k) the CC genotype or CA genotype for SNP marker mME48762 in SEQ ID NO: 11;
l) the CC genotype or CT genotype for SNP marker mME25039 in SEQ ID NO: 12; and/or
m) the TT genotype or TC genotype for SNP marker mME40109 in SEQ ID NO: 13.
US Pat. No. 10,364,278

CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE

New York University, New...

1. A chimeric protein comprising:an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an FGF1 portion beginning at any one of residues 1 to 25 and ending at any one of residues 150 to 155 of SEQ ID NO: 1,
wherein the FGF1 amino acid positions corresponding to those selected from the group consisting of N33, K127, K128, N129, K133, R134, R137, Q142, K143, and combinations thereof are substituted to decrease binding affinity for heparin and/or heparan sulfate compared to FGF1 without substitution, and
wherein the C-terminus comprises a C-terminal portion of an FGF23 comprising amino acid residues 161-251 of SEQ ID NO: 233.
US Pat. No. 10,364,279

PD-L1 AND PD-L2-BASED FUSION PROTEINS AND USES THEREOF

Thomas Jefferson Universi...

1. A fusion protein comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor, wherein the polypeptide that binds to and triggers PD-1 comprises amino acids 1-220 of SEQ ID NO: 5 and the polypeptide that binds to and triggers a TRAIL receptor comprises the amino acid sequence of SEQ ID NO: 15.
US Pat. No. 10,362,744

LETTUCE VARIETY 45-246 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A seed of lettuce variety 45-246 RZ, a sample of seed of said variety having been deposited under NCIMB Accession No. 42636.
US Pat. No. 10,366,841

ELECTROLYTIC CAPACITOR

Panasonic Corporation, O...

1. An electrolytic capacitor comprising:an anode body;
a dielectric layer formed on the anode body; and
a conductive polymer layer covering at least a part of the dielectric layer;
wherein:
the conductive polymer layer comprises a conductive polymer and a polymer dopant;
the polymer dopant comprises:
(A) a first unit originating from a first monomer having a polymerizable group and a sulfonate group; and
(B) a second unit originating from a second monomer having a polymerizable group and a phosphorus-containing group;
the phosphorus-containing group is represented by at least one of following general formulae:
—P(?O)(OR1)(OR2),  general formula (1):
—PH(?O)(OR3), and  general formula (2):
—PH2(?O),  general formula (3):in the general formulae (1) to (3), each of R1, R2 and R3 is independently a hydrogen atom, a hydrophilic group, a C1 to C3 alkyl group, or a cationic group, anda proportion of the second unit ranges from 5% by mole to 50% by mole both inclusive with respect to a total of the first unit and the second unit in the polymer dopant.
US Pat. No. 10,365,562

COATING COMPOSITIONS FOR USE WITH AN OVERCOATED PHOTORESIST

Rohm and Haas Electronic ...

1. A coated substrate comprising:(a) a layer of a coating composition on a substrate, the coating composition comprising a polyester resin that comprises one or more uracil moieties,
wherein the composition coating layer further comprises phenyl or anthacene groups, or where the uracil moieties are halogen-substituted; and
(b) a photoresist layer over the coating composition layer.
US Pat. No. 10,362,746

WHEAT CULTIVAR 01071514

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071514, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-125548.
US Pat. No. 10,363,258

TREATMENT OF MIGRAINES

Manistee Partners LLC, C...

1. A method of treating migraine in a subject in need thereof, the method comprising oral or mucosal membrane administration of a composition comprising latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost, or a pharmaceutically acceptable salt thereof, to the subject, in an amount effective to treat migraine; provided that the mucosal membrane is not an eye.
US Pat. No. 10,364,283

COLLAGEN HYDROLYSATE AND USE THEREOF

GELITA AG, Eberbach (DE)...

1. A collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from hydrolyzed collagen peptides of which at least 50% by weight have a molecular weight of 1,500 Da to 13,500 Da, and which have a weight average molecular weight in the range from 4,000 Da to 8,000 Da, wherein the bone gelatin is produced by alkaline breakdown of collagen from bones of vertebrates.
US Pat. No. 10,366,844

ELECTROCHEMICAL CELL

Seiko Instruments Inc., ...

1. An electrochemical cell comprising:an electrode body including a positive electrode body and a negative electrode body; and
an exterior body housing the electrode body, wherein
the exterior body includes:
a first container having a bottomed cylindrical shape and including a first circumferential wall section;
a second container having a bottomed cylindrical shape and including a second circumferential wall section surrounding the first circumferential wall section, the second container housing the electrode body between the second container and the first container; and
a fusing member interposed between the first circumferential wall section and the second circumferential wall section and fused to the first circumferential wall section and the second circumferential wall section, the fusing member comprising a thermally deformable layer of material different from that the first container.
US Pat. No. 10,362,750

WHEAT CULTIVAR 01071570

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071570, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-125545.
US Pat. No. 10,364,286

MONOCLONAL ANTI-ALPHA-SYNUCLEIN ANTIBODIES FOR PREVENTING TAU AGGREGATION

1. A method for treating Alzheimer's disease without Lewy body pathology in a patient comprising:providing a monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds alpha-synuclein to a patient having Alzheimer's disease without Lewy body pathology in an amount effective to inhibit aggregation of tau in the patient, wherein:
(i) the antibody, or antigen-binding fragment thereof, comprises:
a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
a Heavy Chain CDR2 having the amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:33, SEQ ID NO:34, or SEQ ID NO:35;
a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6; or
(ii) the antibody, or antigen-binding fragment thereof, comprises:
a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:20;
a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:21;
a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:22;
a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:23;
a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:24; and
a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:25.
US Pat. No. 10,363,263

ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME

Prescient Pharma, LLC, C...

1. A pharmaceutical composition comprising an effective amount of at least one lithium compound selected from lithium chloride, lithium bromide, lithium carbonate, lithium nitrate, lithium sulfate, lithium acetate, lithium lactate, lithium citrate, lithium aspartate, lithium gluconate, lithium malate, lithium ascorbate, lithium orotate, lithium succinate, and combinations thereof; an effective amount of at least one glycyrrhizic triterpenoid compound selected from glycyrrhizin, enoxolone, carbenoxolone, cicloxolone, and combinations thereof, or a pharmaceutically acceptable salt thereof; andan effective amount of at least one retinoic acid compound or a pharmaceutically acceptable salt thereof;
wherein the composition is formulated for oral administration.
US Pat. No. 10,364,288

ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF

Biogen MA Inc., Cambridg...

1. An antibody or antigen-binding fragment thereof that binds to glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:the VH CDR1 comprises the amino acid sequence AYAMS (SEQ ID NO:31);
the VH CDR2 comprises the amino acid sequence SISSGGTTYYPDSVKR (SEQ ID NO:32); and
the VH CDR3 comprises the amino acid sequence GGDYGYALDY (SEQ ID NO:33); and
wherein the antibody or the antigen-binding fragment thereof comprises a light chain variable region (VL) comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RASSSVNYMY (SEQ ID NO:34);
the VL CDR2 comprises the amino acid sequence YTSNLAP (SEQ ID NO:35); and
the VL CDR3 comprises the amino acid sequence QQFSSSPWT (SEQ ID NO:36).
US Pat. No. 10,364,290

ANTI-HER3/HER4 ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 AND THE BETA-HAIRPIN OF HER4

Hoffmann-La Roche Inc., ...

1. An isolated nucleic acid encoding an antibody that binds to human HER3 and binds to human HER4, wherein the antibody comprises:(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.
US Pat. No. 10,362,755

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH475588

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH475588, produced by crossing a first plant of variety CV181138 with a second plant of variety CV759867, wherein representative seeds of said varieties CV181138 and CV759867 are deposited under ATCC Accession Nos. PTA-123825 and PTA-124497, respectively.
US Pat. No. 10,363,267

DIARRHEA-PREVENTING NUTRITIONAL COMPOSITION

OTSUKA PHARMACEUTICAL FAC...

1. A nutritional composition for preventing diarrhea comprisinga pectin having a degree of esterification of 10 to 30%, a degree of amidation of 0 to 25%, and a degree of free acids of 64% or more and less than 85%,
lipid,
carbohydrate other than the pectin, and
protein,
wherein the pectin has a weight-average molecular weight of 350000 to 600000.
US Pat. No. 10,362,756

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH482861

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH482861, produced by crossing a first plant of variety CV181138 with a second plant of variety CV093813, wherein representative seeds of said varieties CV181138 and CV093813 are deposited under ATCC Accession Nos. PTA-123825 and PTA-123818, respectively.
US Pat. No. 10,362,757

SOYBEAN CULTIVAR S170156

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170156, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125398.
US Pat. No. 10,364,293

POLYPEPTIDE BINDING TO EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR

KOREA ADVANCED INSTITUTE ...

1. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8.
US Pat. No. 10,363,270

METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL IMMUNOTHERAPY

CELLECTIS, Paris (FR)

1. A method for treating a cancer patient using immunotherapy comprising:providing primary human T cells from a single donor;
co-electroporating into said primary human T-cells:
(a) RNAs encoding two half TALE-nucleases having Fok-I catalytic domains, wherein the two half TALE-nucleases dimerize and recognize two half-targets separated by a spacer of 11-15 bp and cleave the target sequence of SEQ ID NO:40 within a gene encoding CD52, and
(b) RNAs encoding two half TALE-nucleases having Fok-I catalytic domains,
wherein the two half TALE-nucleases dimerize and recognize two half-targets separated by a spacer of 11-15 bp and cleave the target sequence of SEQ ID NO:37 within a gene encoding TCR?,
to generate doubly-inactivated human T-cells having both the CD52 and the TCR? genes inactivated;
modifying the doubly inactivated human T-cells to express a chimeric antigen receptor; and
infusing at least 104 of the doubly inactivated human T-cells expressing a chimeric antigen receptor into said cancer patient for immunotherapy treatment.
US Pat. No. 10,363,271

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

SMART Surgical, Inc., Bo...

1. A method of making a composition for influencing biological growth configured for implantation within a subject, the method comprising:(A) obtaining a sample comprising human umbilical cord blood and having a first volume VUC, wherein the human umbilical cord blood includes red blood cells, cells other than red blood cells, and non-cellular material;
(B) combining the sample comprising human umbilical cord blood with a quantity of an aggregation agent or sedimentation agent having a volume VPC, wherein the ratio VUC/VPC is between about 0.60 and about 1.75 such that a supernatant is formed;
(C) layering within a container at least a portion of the supernatant over a layer of an isolation reagent, the at least a portion of the supernatant having a volume VS and the layer of the isolation reagent having a volume VR, wherein the volume of the layer of the isolation reagent VR is at least 67% the volume VS of the at least a portion of the supernatant;
(D) placing at least about 350 times the acceleration due to gravity on the contents of the container with a force vector directed toward a closed end of the container to safely cause at least a new layer substantially comprising mononuclear cells to form;
(E) combining at least some of the layer substantially comprising mononuclear cells with lactated Ringer's solution or an equivalent balanced or buffered solution to create a mononuclear cell solution;
(F) determining the total number of live cells NL in at least a portion of the mononuclear cell solution, the at least a portion of the mononuclear solution having a volume VM; and
(G) adding a volume VDD of Low Molecular Weight Dextran in Dextrose solution to the at least a portion of the mononuclear cell solution, the volume VDD based at least in part on the total number NL of live cells and the anticipated future viability of the live cells.
US Pat. No. 10,364,295

RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS

PRECISION BIOLOGICS, INC....

1. An isolated nucleic acid encoding at least one of the light or heavy chain of an a monoclonal antibody or antigen-binding fragment thereof that binds to the human colorectal and pancreatic carcinoma-associated antigen (CPAA) expressed by LS174T colorectal cancer cells and bound by the NPC-1 antibody consisting of the light chain variable region of SEQ ID NO: 1 and the heavy chain variable region of SEQ ID NO: 4, wherein said monoclonal antibody or antigen-binding fragment thereof comprises the light chain CDR1 amino acid sequence of SEQ ID NO:7, light chain CDR2 amino acid sequence of SEQ ID NO:8, and light chain CDR3 amino acid sequence of SEQ ID NO:9, and wherein said monoclonal antibody or antigen-binding region thereof comprises the heavy chain CDR1 amino acid sequence of SEQ ID NO:10, heavy chain CDR2 amino acid sequence of SEQ ID NO:11, and heavy chain CDR3 amino acid sequence of SEQ ID NO:12.
US Pat. No. 10,363,273

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

IOVANCE BIOTHERAPEUTICS, ...

1. A method for treating a subject with head and neck cancer, the method comprising administering expanded tumor infiltrating lymphocytes (TILs) comprising:(a) obtaining a first population of TILs from a tumor resected from a subject by processing a tumor sample obtained from the subject into multiple tumor fragments;
(b) adding the tumor fragments into a closed system;
(c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-11 days to obtain the second population of TILs, wherein the second population of TILs is at least 50-fold greater in number than the first population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
(d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-11 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
(e) harvesting the third population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
(f) transferring the harvested third TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
(g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process; and
(h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject.
US Pat. No. 10,365,070

BALLISTIC RESISTANT ARTICLE WITH NON-UNIFORMLY DISTRIBUTED MATRIX MATERIAL AND METHOD TO MANUFACTURE SAID ARTICLE

TEIJIN ARAMID B.V., Arnh...

1. A ballistic resistant article comprising at least one consolidated composite,wherein the at least one consolidated composite comprises a layer A and a layer B bonded to one another, each layer A and each layer B having
a first surface,
a second surface opposite to the first surface, and
a cross-section extending from the first surface to the second surface,
and each layer A and each layer B comprises a network of fibers having a strength of at least 800 mN/tex (1100 MPa) according to ASTM D 7269-07, and the fibers in each layer A and each layer B are impregnated with a matrix material,
wherein the matrix material is distributed along the cross-section of each layer in a concentration gradient in which the concentration starts with a maximum value on the first surface, so that the first surface is rich in matrix material, decreases along the cross-section and reaches a minimum value on the second surface, so that the second surface is poor in matrix material, and the matrix material comprises a mixture of 75 to 95 wt. % of a polychloroprene, and 5 to 25 wt. % of a random copolymer of vinyl chloride and an acrylic ester, based on a weight of the mixture.
US Pat. No. 10,364,304

METHOD FOR PRODUCING SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION, AND METHOD FOR PRODUCING OLEFIN POLYMER

TOHO TITANIUM CO., LTD., ...

1. A method for producing a solid catalyst component, the method comprising:contacting a magnesium compound, a first tetravalent titanium halide compound, and an electron donor compound represented by formula (1) with each other:
(R1)kC6H4-k(COOR2)(COOR3)  (1);
reacting the magnesium compound, the first tetravalent titanium halide compound, and the electron donor compound represented by formula (1) to obtain a first reaction product;
washing the first reaction product to obtain a solid component;
contacting the solid component, a second tetravalent titanium halide compound, and one or more compound (2) selected from dimethyl isopropylbromomalonate, dimethyl butylbromomalonate, dimethyl isobutylbromomalonate, dimethyl isopropylmalonate, dimethyl butylmalonate, dimethyl isobutylmalonate, dimethyl isopentylmalonate, dimethyl diisopropylmalonate, dimethyl dibutylmalonate, dimethyl diisobutylmalonate, dimethyl diisopentylmalonate, dimethyl isopropylisobutylmalonate, dimethyl bis(3-chloro-n-propyl)malonate or dimethyl bis(3-bromo-n-propyl)malonate
reacting the solid component, the second tetravalent titanium halide compound, and said one or more compound (2) to obtain a second reaction product; and
washing the second reaction product, to obtain a solid catalyst component,
wherein:
R1 represents an alkyl group having 1 to 8 carbon atoms or a halogen atom;
R2 and R3 independently represent an alkyl group having 1 to 12 carbon atoms, wherein R2 and R3 are either identical or different;
k represents 0, 1, or 2, wherein R1 are either identical or different when k is 2;
wherein the electron donor compound represented by formula (1) and said one or more compound (2) are not contacted with each other in the preparation of the solid component and the solid catalyst component.
US Pat. No. 10,362,770

TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS

Crystal Bioscience Inc., ...

1. A transgenic chicken that comprises a genome comprising a recombinant immunoglobulin heavy chain (IgH) locus comprising:(a) a functional IgH gene comprising a nucleic acid encoding a heavy chain variable region comprising:
(i) heavy chain complementarity determining (CDR) regions; and
(ii) a heavy chain framework; and,
(b) a plurality of pseudogenes that encode heavy chain variable regions each comprising:
(i) heavy chain CDR regions; and
(ii) a heavy chain framework region that is identical in amino acid sequence to the heavy chain framework of a) (ii);
wherein said nucleic acid of (a) and pseudogene of (b), are exogenous to the genome of said transgenic chicken,
wherein said plurality of pseudogenes are operably linked to said functional IgH gene and donate nucleotide sequences to the nucleic acid of (a) by gene conversion in said transgenic chicken; and
wherein said transgenic chicken expresses a polyclonal antiserum comprising a diversified IgH variable region.
US Pat. No. 10,363,282

ANALOGS OF C5A AND METHODS OF USING SAME

Board of Regents of The U...

1. A method of activating an immune cell at a site of infection or disease comprising administering an effective amount of an oligopeptide C-terminal analog of C5a to a mammal, wherein said immune cell is an antigen presenting cell, said analog not attached to an antigen, and said analog having response-selective C5a receptor binding activity, wherein the analog is SEQ ID NO: 4.
US Pat. No. 10,362,771

METHOD FOR KNOCK-IN OF DNA INTO TARGET REGION OF MAMMALIAN GENOME, AND CELL

KYOTO UNIVERSITY, Kyoto ...

1. A method for knock-in of a donor DNA into the genome of a cell, comprising introducing at least one artificial nuclease system G capable of cleaving one or two target sequences G of the cell genome, the donor DNA, and two single-stranded oligonucleotides (ssODNs) into the cell,the artificial nuclease system G cleaving the one or two target sequences G on the cell genome to generate two DNA double-strand break (DSB) sites on the cell genome,
the two ssODNs being Up-ssODN complementary to DSB site g1, one of the DSB sites generated by the target sequence G cleavage of the cell genome, and to upstream introduction site D1 of the donor DNA, and Down-ssODN complementary to DSB site g2, the other DSB site of the cell genome, and to downstream introduction site D2 of the donor DNA, and
the donor DNA being knocked-in between the two DSB sites g1 and g2 in the one or two target sequences G of the cell genome using the two ssODNs (Up-ssODN and Down-ssODN),
wherein the donor DNA is a plasmid comprising one or two target sequences, the artificial nuclease system comprises artificial nuclease system G comprising Cas9 nuclease and one or two guide RNAs-G (gRNAs-G) corresponding to the one or two target sequences G of the cell genome, and artificial nuclease system D comprising Cas9 nuclease and one or two guide RNAs-D (gRNAs-D) corresponding to the one or two target sequences D of the donor DNA, the one or two target sequences G of the cell genome are cleaved by the artificial nuclease system G to generate DSB sites g1 and g2 on the cell genome, and the one or two target sequences D on the donor DNA plasmid are cleaved by the artificial nuclease system D to generate upstream introduction site D1 and downstream introduction site D2 of the plasmid-derived donor DNA to be knocked-in into the genome.
US Pat. No. 10,363,541

SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE

IMMUNOLIGHT, LLC., Detro...

1. A method for modifying a hydrophobic polymer surface, comprising:disposing in contact with the hydrophobic polymer surface a liquid composition comprising monomeric precursors to a hydrophilic polymer and one or more energy modulation agents, wherein the one or more energy modulation agents are resistant to chemical interaction with the liquid composition and hydrophobic polymer surface; and
applying energy from at least one of x-rays, gamma rays, or an electron beam into the liquid composition, wherein the applied energy interacts with the one or more energy modulation agents and internally generates light inside the liquid composition, thereby causing the monomeric precursors to polymerize and react with the hydrophobic polymer surface, thereby grafting the hydrophilic polymer onto the hydrophobic polymer surface.
US Pat. No. 10,363,290

BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES

KODIAK SCIENCES INC., Pa...

1. A fusion protein comprising: a butyrylcholinesterase enzyme or carboxy terminal truncation fragment thereof and an immunoglobulin (Ig) domain or fragment thereof, wherein a linker is positioned between and connecting the butyrylcholinesterase enzyme or fragment thereof and the Ig domain of fragment, wherein the Ig domain or fragment thereof comprises substitutions L234A, L235E, and G237A per EU numbering which corresponds to substitutions L14A, L15E, and G17A as numbered within SEQ ID NO: 8, wherein the linker is selected from the group consisting of at least one of Q, GOG, GGGGS (SEQ ID NO: 22), GGGS (SEQ ID NO: 23), GGGES (SEQ II) NO: 24), GGGSGGGSGGGS (SEQ ID NO: 21), and GGSGGGSGGGS (SEQ ID NO: 25).
US Pat. No. 10,363,546

MULTILAYER POLYMERIC MEMBRANE

Liso Plastics LLC, Charl...

1. A multilayer sorbent polymeric membrane comprising at least one layer comprising: a matrix polymer, sorbent materials of about 100 wt. % or less, and a plurality of interconnecting pores having an average pore size of about 0.1 nm or greater,wherein the matrix polymer is a film-forming thermoplastic polymer selected from the group consisting of petroleum-based polymers, bio-based polymers, biodegradable polymers, and combinations thereof;
wherein the sorbent materials present in the membrane retain their initial sorbability and/or their initial porosity of about 100% or less; and
wherein the membrane has a porosity of about 85% or less and a Gurley air permeability of about 1 sec/100 cc or greater.
US Pat. No. 10,363,547

METHODS FOR MAKING CATALYST SYSTEMS

Saudi Arabian Oil Company...

1. A method for making a catalyst system, the method comprising:introducing one or more alkali or alkaline earth metals to a zincosilicate support material; and
introducing one or more platinum group metals to the zincosilicate support material; and
wherein the zincosilicate support material comprises an MFI framework type structure incorporating at least silicon and zinc.
US Pat. No. 10,363,549

CHROMIUM OXYFLUORIDE CATALYSTS HAVING HIGH FLUORINATION ACTIVITY

Arkema Inc., King of Pru...

1. A chromium oxyfluoride catalyst active for fluorination of a chlorinated compound, wherein the chromium oxyfluoride catalyst is comprised of a first chromium species and a second chromium species, wherein the first chromium species exhibits a first X-ray photoelectron spectroscopy (XPS) chromium Cr 2p3/2 peak between 576.9 eV+/?0.2 eV and 578.0 eV+/?0.2 eV and the second chromium species exhibits a second X-ray photoelectron spectroscopy (XPS) chromium Cr 2p3/2 peak between 580.0 eV+/?0.2 eV and 581.4 eV+/?0.2 eV and wherein the intensity of the second XPS chromium peak is greater than the intensity of the first XPS chromium peak.
US Pat. No. 10,362,782

METHOD FOR CONTROLLING RUST

UPL Limited, Haldia, Wes...

1. A fungicidal combination, consisting of:(i) mancozeb,
(ii) prothioconazole, and
(a) at least one succinate dehydrogenase inhibitor fungicide selected from the group consisting of benodanil, flutolanil, mepronil, fluopyram, fenfuram, carboxin, oxycarboxin, thifluzamide, bixafen, fluxapyroxad, furametpyr, isopyrazam, penflufen, penthiopyrad, sedaxane, and boscalid; or
(b) at least one quinone outside inhibitor fungicides selected from the group consisting of fenamidone, famoxadone, and a strobilurin fungicide selected from the group consisting of azoxystrobin, mandestrobin, coumoxystrobin, enoxastrobin, flufenoxystrobin, pyraoxystrobin, dimoxystrobin, enestrobin, fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyrametostrobin, triclopyricarb, fenaminstrobin, pyraclostrobin and trifloxystrobin; or
(c) at least one demethylation inhibitor fungicide selected from the group consisting of triflumizole, triforine, pyridinitrile, pyrifenox, fenarimol, nuarimol, triarimol, and a conazole fungicide selected from the group consisting of climbazole, clotrimazole, imazalil, oxpoconazole, prochloraz, prochloraz-manganese, triflumizole, azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazol, difenoconazole, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluotrimazole, fluquinconazole, flusilazole, flutriafol, furconazole, imibenconazole, ipconazole, furconazole-cis, metconazole, hexaconazole, myclobutanil, pencoconazole, propiconazole, prothioconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, perfurazoate, and uniconazole-P; and
(iii) at least one agriculturally acceptable excipient.
US Pat. No. 10,363,296

PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cancer cells that aberrantly present a peptide consisting of the amino acid sequence of TLMPNINKL (SEQ ID NO: 150),wherein said cancer is selected from the group consisting of brain cancer, stomach cancer, liver cancer, leukemias, melanoma, and esophageal cancer.
US Pat. No. 10,362,785

ACTIVATED HYDROGEN PEROXIDE BIOCIDE COMPOSITION

99 HOLDING S.A.R.L., Lux...

1. An aqueous composition consisting essentially of:0.1-1 g/kg Di-n-decyldimethyl ammonium chloride,
0.01-0.10 g/kg benzalkonium chloride,
50-79 g/kg stabilized H2O2,
0.02-0.10 g/kg hydroxyethylidene diphosphonic acid,
0.2-0.6 g/kg C10ethoxylated alcohol having a degree of ethoxylation of 6 mol,
0.01-0.02 g/kg sorbitan monolaurate having a degree of ethoxylation of 20 mol,
up to 1 kg deionized or purified water, and
a sufficient amount of phosphoric acid to reach a pH between 2-3;
wherein the aqueous composition is in the form of a dry mist made up of microdroplets having an average size of less than 5 ?m.
US Pat. No. 10,363,297

IMMUNOGENIC COMPOSITIONS CONTAINING ESCHERICHIA COLI H7 FLAGELLA AND METHODS OF USE THEREOF

The University Court of t...

1. A method for generating a mucosal and/or IgA response in a subject in need thereof, said method comprising the parenteral administration of Escherichia coli H7 or a Toll-like receptor 5 (TLR5) activating fragment thereof.
US Pat. No. 10,362,786

STABLE AQUEOUS SPORE-CONTAINING FORMULATION

Bayer Intellectual Proper...

1. An agriculturally acceptable stable aqueous formula comprising(a) a Bacillus firmus I-1582 spores in an amount of 10% w/w to 55% w/w,
(b) glycerin in an amount of 5% w/w to 50% w/w,
(c) water,
(d) a stabilizer in an amount of 0.5% w/w to 20% w/w, comprising a chemical salt selected from the group consisting of sodium sulfate, sodium chloride, potassium chloride and zinc sulfate; and
(e) clothianidin.
US Pat. No. 10,364,322

NAPHTHALENE-CONTAINING POLYMERS AND METHODS OF MAKING THE SAME

Alliance for Sustainable ...

1. A dimer comprising:a first hydroxyl-functionalized naphthalene group; and
a second hydroxyl-functionalized naphthalene group, wherein:
the first hydroxyl-functionalized naphthalene group and the second hydroxyl-functionalized naphthalene group are connected by a bridging group.
US Pat. No. 10,362,787

METHOD FOR PROPAGATING MICROORGANISMS WITHIN PLANT BIOREACTORS AND STABLY STORING MICROORGANISMS WITHIN AGRICULTURAL SEEDS

AIT AUSTRIAN INSTITUTE OF...

1. A method of producing a indol-3 carboxylic acid within a bacterial colonized cereal plant bioreactor, the method comprising:a. germinating a cereal seed into which at least one inoculant bacterial endophyte has been introduced, wherein the bacterial endophyte is from the genus Burkholderia, comprises a 16S rRNA nucleic acid sequence comprising SEQ ID NO: 1446 and can grow on nitrogen free media, to produce the bacterial colonized cereal plant bioreactor; and
b. growing the bacterial colonized cereal plant bioreactor under conditions such that the bacterial endophyte proliferates and the indol-3 carboxylic acid is produced in the bacterial colonized cereal plant bioreactor, wherein the indol-3 carboxylic acid is produced at a higher concentration in the bacterial colonized cereal plant bioreactor compared to an isoline plant grown from a non-inoculated cereal seed.

US Pat. No. 10,368,295

UNMANNED AERIAL VEHICLE GUIDANCE AND COMMUNICATION DEVICE WITH SYSTEM AND METHOD

FreeFlight Systems, Inc.,...

1. A guidance communication system comprising:a controller configured to manage flight path guidance data stored in a memory via a processor, the flight path guidance data configured to be updated via other data received via a receiver-transmitter, the flight path guidance data associated with at least one unmanned aerial vehicle in an environment controlled by the controller; and
at least one beacon configured to (i) be remotely deployed in the environment of the controller to define a flight path of the vehicle by transmitting the flight path guidance data to the vehicle, (ii) communicate with the receiver-transmitter of the controller via a beacon transmitter-receiver, and (iii) communicate with the vehicle via the beacon transmitter-receiver,
wherein,
the flight path includes a plurality of virtual lanes defined at least in part by the controller,
each of the plurality of virtual lanes has a direction of travel defined by the controller,
the plurality of virtual lanes include two adjacent lanes with opposite directions of travel defined by the controller,
the at least one beacon includes a plurality of beacons deployed in the environment of the controller to define at least a portion of the flight path,
each of the plurality of beacons spaced from each other at predetermined distances to provide redundancy such that, when one of the plurality of beacons is offline, one adjacent beacon maintains an adjacent portion of the flight path previously maintained by the one of the plurality of beacons that is offline, and
the adjacent portion of the flight path previously maintained by the one of the plurality of beacons that is offline is entirely maintained by only the one adjacent beacon so that all functionality of the offline beacon is maintained by the one adjacent beacon.

US Pat. No. 10,368,292

PAUSING FUNCTIONS OF AN ASSISTANT DEVICE DURING AN ACTIVE TELEPHONE CALL

INTERNATIONAL BUSINESS MA...

1. A computer-implemented method comprising:monitoring, by a user device, calling activity on the user device;
detecting, by the user device and based on the monitoring, that a call has started on the user device;
providing, by the user device, a pause instruction to an assistant device via an assistant cloud control device based on detecting that the call has started on the user device, causing the assistant device to disable speech response functions; and
providing a resume instruction to the assistant device via the assistant cloud control device based on detecting that a mute function of the user device has been activated based on the monitoring the calling activity;
wherein the providing the pause instruction and the resume instruction via the assistant cloud control device comprises providing location information of the user device, causing the assistant cloud control device to provide the pause instruction and the resume instruction to a subset of a plurality of assistant control devices having a known location within a threshold distance of the user device.

US Pat. No. 10,368,288

SYSTEMS AND METHODS FOR CONNECTING DEVICES THROUGH INTERMEDIATE NODES

Bridgefy, Inc., San Fran...

1. A method for wireless communications, comprising:receiving, at an apparatus, a request to forward a first packet previously received at the apparatus, the first packet includes a first identifier of a first recipient device of the first packet;
determining, based on the first identifier, whether the first recipient device is in a list of wireless devices within a wireless range of the apparatus;
including, based on the determination, the first packet into an outgoing queue comprising a list of packets to be forwarded;
establishing one or more connections with one or more wireless devices in the list of wireless devices;
upon including the first packet into the outgoing queue, decrementing a value in the first packet indicating a remaining number of times the first packet is allowed to be transferred from one wireless device to another wireless device;
forwarding, in accordance with the decremented value, the first packet from the outgoing queue to the one or more wireless devices via the established one or more connections;
receiving, at the apparatus, a second packet having a second identifier of a second recipient device;
determining, based on the second identifier, that the second recipient device is the same as the apparatus; and
transmitting a reach packet directly to the one or more wireless devices from the list of wireless devices to stop forwarding the second packet.

US Pat. No. 10,368,287

METHOD AND APPARATUS FOR RESELECTING CELL IN WIRELESS COMMUNICATION SYSTEM

LG ELECTRONICS INC., Seo...

1. A method for allocating an uplink (UL) resource in a wireless communication system supporting a low latency service, the method performed by a user equipment (UE) and comprising:receiving a first control message including first scheduling delay information indicating a delay time related to resource allocation of a serving base station from the serving base station;
transmitting a request message including a UL resource request information element (IE) for requesting UL resource allocation to the serving base station or a neighboring base station based on the first control message; and
receiving a response message in response to the request message from the serving base station or the neighboring base station,
wherein the UL resource is allocated to the UE by the serving base station or the neighboring base station based on the request message, and
wherein the UL resource request IE includes a UL grant offset field indicating a UL resource request time of the UE.

US Pat. No. 10,368,286

DYNAMIC ROUTER FUNCTIONALITY IN CELLULAR NETWORKS

Veea Systems Ltd., Bath ...

1. A wireless remote communication unit for communicating with a cellular network node and other wireless remote communication units, the wireless remote communication unit comprising:at least one transceiver configured to communicate with a cellular network node using either a first technology employed with mesh connectivity via at least one other wireless remote communication unit or a second technology employed with a direct connection; and
a processor coupled to the at least one transceiver and arranged to:
determine when the wireless remote communication unit moves out of coverage of the cellular network node and, in response thereto,
configure the wireless remote communication unit with mesh router functionality that transfers data from one node to another node within a mesh network using the first technology based on, at least in part, information obtained from received first messages using the first technology employed with mesh connectivity from at least one other wireless remote communication unit;
wherein the first messages from the at least one other wireless remote communication unit comprise a beacon that includes an indication of whether the at least one other wireless remote communication unit is located inside or outside of cellular coverage.

US Pat. No. 10,368,285

STATION (STA), ACCESS POINT (AP) AND METHOD OF COMMUNICATION IN THE PRESENCE OF SPATIAL REUSE

Intel IP Corporation, Sa...

1. An apparatus of a first station (STA), the apparatus comprising: memory; andprocessing circuitry, configured to:
determine a received signal strength indicator (RSSI) based on one or more inbound physical layer convergence procedure (PLCP) protocol data units (PPDUs) received at the first STA in a channel;
contend for a transmission opportunity (TXOP) to obtain access to the channel;
determine, based at least partly on a comparison between the RSSI of the one or more inbound PPDUs received at the first STA and a predetermined threshold, whether spatial reuse (SR) transmissions by one or more second STAs are permissible, the SR transmissions by the one or more second STAs at least partially concurrent to transmissions by the first STA within the TXOP in the channel; and
encode, for transmission in the channel during the TXOP, an outbound PPDU that includes an SR indicator that is based on the comparison, wherein a first value of the SR indicator indicates that the SR transmissions by the one or more second STAs at least partially concurrent with transmission of the outbound PPDU by the first STA are permissible and a second value of the SR indicator indicates that the SR transmissions by the one or more second STAs at least partially concurrent with transmission of the outbound PPDU by the first STA are impermissible.

US Pat. No. 10,368,284

QUALITY OF EXPERIENCE-BASED HANDOVER MANAGEMENT

T-Mobile USA, Inc., Bell...

1. A system, comprising:one or more processors; and
memory having instructions stored therein, the instructions, when executed by the one or more processors, cause the one or more processors to perform acts comprising:
receiving a quality metric value obtained by a user device for a current base station of a carrier network, the quality metric value is an aggregate value of individual quality metric values measuring multiple quality of experience characteristics of multiple applications on the user device as the user device is communicating with the current base station;
determining whether a signal robustness of a signal provided by an adjacent base station relative to a predetermined minimal threshold initiates a comparison of the quality metric value of the current base station to a corresponding quality metric value for the adjacent base station;
comparing the quality metric value of the current base station to the corresponding quality metric value for the adjacent base station of the carrier network in response to determining that the signal robustness of the signal provided by the adjacent base station is above the predetermined minimal threshold, the corresponding quality metric value is an additional aggregate value of additional individual quality metric values measuring multiple quality of experience characteristics of multiple additional applications on an additional user device that communicated with the adjacent base station; and
commanding the user device to perform a handover that switches the user device from communicating with the current base station to communicating with the adjacent base station in response to the corresponding quality metric value being greater than the quality metric value.

US Pat. No. 10,368,283

CONVERGENCE OF CLOUD AND MOBILE ENVIRONMENTS

International Business Ma...

1. A method comprising:receiving, by one or more processors, a request to complete a computing task on a first device, wherein:
the first device comprises at least a portion of a cloud computing environment,
the request to complete the computing task originates from a second device, and
the computing task requires a physical sensor;
identifying, by one or more processors, one or more capabilities of the first device, wherein a first capability of the one or more capabilities is identified based, at least in part, on whether the first device has the physical sensor;
determining, by one or more processors, that the computing task should be offloaded from the first device to a third device based, at least in part, on the first device lacking the physical sensor and the third device having the physical sensor;
offloading, by one or more processors, the computing task from the first device to the third device;
receiving, by one or more processors, a result of the computing task from the third device; and
sending, by one or more processors, the result of the computing task from the first device to the second device.

US Pat. No. 10,368,282

MODE CONTROL DESIGN

ITRON NETWORKED SOLUTIONS...

1. A method for optimizing communication modes between network nodes, comprising:storing, in a first node in a communication network, a data success rate for each of a plurality of communication modes;
receiving, by the first node, mode data from a second node in the communication network including at least a mode identifier for at least two of the plurality of communication modes;
determining, by the first node, a metric for each of the at least two communication modes based on at least a data success rate of transmissions using the respective communication mode;
selecting, by the first node, a preferred communication mode of the at least two communication modes based on the determined metric for each of the at least two communication modes; and
transmitting, by the first node, an initiation data message to the second node via the communication network indicating the selected preferred communication mode.

US Pat. No. 10,368,281

TELEPHONE WITH AUTOMATIC SWITCHING BETWEEN CELLULAR AND VOIP NETWORKS

Vasu Networks Corporation...

1. A device comprising:a switching system to switch operation between a first communication module and a second communication module, wherein during an established communication if a context changes, the established communication is switched to a second communication over a second network, wherein switching is based on detecting a second context being preferred over the context within a set of networks, wherein upon activation of a timer, the switching system causes the second communication module to change state from a sleep mode to an active mode, wherein the timer is activated to establish a time window of a predefined size, wherein if a Wi-Fi signal monitor detects that a Wi-Fi signal level is below a second predefined threshold value Vth2, the timer is activated to establish a second time window of a second predefined size T2, wherein a third predefined threshold value Vth3 is smaller than Vth2.

US Pat. No. 10,368,278

METHOD AND ENODEB FOR FORWARDING DOWNLINK AND UPLINK PACKETS BASED ON S1 HANDOVER

Huawei Technologies Co., ...

1. A method for forwarding uplink packets based on an S1 handover, the method comprising:forwarding, by a source evolved node (eNodeB), an uplink packet to a source serving gateway, wherein the uplink packet is successfully received from user equipment (UE);
discarding, by the source eNodeB, an uplink packet received out of sequence;
sending, by the source eNodeB, a packet data convergence protocol serial number (PDCP SN) to a target eNodeB in a control message,
wherein the PDCP SN is larger or equal to a maximum PDCP SN of the uplink packet;
sending, by the target eNodeB, packet state report information to the UE, wherein the packet state report information comprises the PDCP SN; and
receiving, by the target eNodeB, uplink packets from the UE, wherein the uplink packets include PDCP SNs that are equal to or larger than the PDCP SN of the packet state report information.

US Pat. No. 10,368,276

CELL HANDOVER METHOD, BASE STATION, AND CONTROL NODE

HUAWEI TECHNOLOGIES CO., ...

1. A cell handover method, applied to a communications system comprising a first base station, at least two second base stations, and user equipment (UE), wherein the first base station is corresponding to a first cell, the first cell is a serving cell of the UE, the at least two second base stations are corresponding to at least two second cells, the at least two second cells are neighboring cells of the first cell, the at least two second cells are in one-to-one correspondence with at least two cell global identities (CGIs), each CGI is used to uniquely identify a corresponding second cell in the communications system, each second base station stores configuration information, the configuration information is used to indicate a time-frequency resource used when the UE sends a sounding reference signal (SRS) to the first base station, and the method comprises:receiving, by the first base station, a handover request sent by the UE, wherein the handover request is used to indicate that the UE requests to be handed over to a target second cell of the at least two second cells, and the handover request carries a physical cell identifier (PCI) of the target second cell;
determining, by the first base station, that the PCI is corresponding to a plurality of second cells;
receiving, by the first base station, location information of the UE sent by a target second base station of the at least two second base stations that is corresponding to the target second cell, wherein the location information is obtained by the target second base station based on the configuration information; and
determining, by the first base station, the target second cell from the plurality of second cells based on the location information.

US Pat. No. 10,368,275

METHOD AND APPARATUS FOR UE MOBILITY IN A SMALL CELL SYSTEM

Samsung Electronics Co., ...

1. A method for managing a connection with a user equipment (UE) by a source master base station in a wireless communication system, the method comprising:transmitting, to a target master base station, a first control message for handover request, the first control message including information of a secondary base station involved in a dual connectivity for the UE;
receiving, from the target master base station, a second control message in response to the first control message, the second control message including information indicating that information of the UE at the secondary base station is kept; and
transmitting, to the secondary base station, a third control message for requesting release of resources related to the UE, the third control message including the information indicating that the information of the UE at the secondary base station is kept,
wherein the second control message includes the information indicating that the information of the UE at the secondary base station is kept, if the target master base station determines to keep the UE information in the secondary base station.

US Pat. No. 10,368,273

METHOD AND SYSTEM FOR SUPPORTING FAST RECOVERY OF USER EQUIPMENT

Samsung Electronics Co., ...

1. A method by a first base station in a wireless communication system, the method comprising:receiving a radio link failure (RLF) indication message related to an RLF of a terminal from a second base station;
identifying whether to trigger a handover preparation procedure based on information included in the RLF indication message; and
transmitting a handover request message to the second base station based on the handover preparation procedure being triggered,
wherein the handover preparation procedure is triggered based on the RLF indication message not including an indicator related to a radio resource control (RRC) connection setup and based on terminal context included in the RLF indication message matching context found by the first base station, and
wherein the handover preparation procedure is not triggered based on the RLF indication message including the indicator related to the RRC connection setup.

US Pat. No. 10,368,272

METHOD AND APPARATUS FOR TRANSMITTING INDICATION IN WIRELESS COMMUNICATION SYSTEM

LG ELECTRONICS INC., Seo...

1. A method for transmitting, by a first eNodeB (eNB), a transport network layer (TNL) address in a wireless communication system, the method comprising:receiving, by the first eNB, a first configuration transfer message,
wherein the first configuration transfer message includes information on an indirect X2 interface between the first eNB and a second eNB,
wherein the indirect X2 interface goes through an X2 gateway (X2-GW) between the first eNB and the second eNB,
wherein the X2-GW is not connected to a mobility management entity (MME), and
wherein the information on the indirect X2 interface is generated by the second eNB; and
transmitting, by the first eNB, a second configuration transfer message towards the second eNB,
wherein the second configuration transfer message includes a TNL address of the X2-GW based on the information on the indirect X2 interface.

US Pat. No. 10,368,271

METHOD AND APPARATUS FOR TRANSMITTING SYNCHRONIZATION SIGNALS FOR A MOVING CELL

LG ELECTRONICS INC., Seo...

1. A method for a moving cell base station to transmit a moving cell synchronization signal sequence, the method comprising:mapping the moving cell synchronization signal sequence to a first frequency region; and
transmitting the moving cell synchronization signal sequence via the first frequency region,
wherein the first resource region is different from a second frequency region, and
wherein the second frequency region is for transmitting a synchronization signal for a user equipment which cannot support the moving cell base station.

US Pat. No. 10,368,270

METHOD AND APPARATUS FOR ACCESSING A RANDOM ACCESS CHANNEL BY SELECTIVELY USING DEDICATED OR CONTENTION-BASED PREAMBLES DURING HANDOVER

InterDigital Patent Holdi...

1. A wireless transmit/receive unit (WTRU) comprising:a transmitter; and
a processor configured to:
activate a timer;
transmit, via the transmitter, a dedicated non-contention based random access channel (RACH) preamble to attempt RACH access prior to an expiration of the timer; and
transmit, via the transmitter, a contention-based RACH preamble after the RACH access attempt fails using the dedicated non-contention based RACH preamble and after the expiration of the timer.

US Pat. No. 10,368,268

METHODS, SYSTEMS AND DEVICES FOR SUPPORTING LOCAL BREAKOUT IN SMALL CELL ARCHITECTURE

Samsung Electronics Co., ...

1. A method by a mobility management entity (MME), the method comprising:receiving, from a first base station, an initial user equipment (UE) message including a local home network (LHN) identification (ID) of the first base station;
determining whether to establish a local breakout bearer based on subscription information of a UE and the LHN ID; and
transmitting, to the first base station, based on determining to establish the local breakout bearer, an initial context setup request message including information associated with the local breakout bearer,
wherein a second base station addition request message is transmitted to a second base station having a same LHN ID as the LHN ID of the first base station for dual connectivity.

US Pat. No. 10,368,267

ADAPTIVE NETWORK WITH INTERCONNECTED AUTONOMOUS DEVICES

INTERNATIONAL BUSINESS MA...

1. A computer-implemented method, comprising:determining autonomously, by a first base station, that the first base station is overloaded with connections from one or more mobile devices, wherein the determining that the first base station is overloaded comprises detecting, by the first base station, that a connection count of the first base station exceeds a threshold count; and
responsive to the first base station being overloaded:
requesting, by the first base station that is overloaded, a plurality of status updates from a plurality of base stations, each base station in the plurality of base stations configured to provide connections to a plurality of mobile devices;
receiving, by the first base station that is overloaded, the plurality of status updates comprising a respective status update from each of the plurality of base stations;
identifying, by the first base station that is overloaded, based on the plurality of status updates, a second base station having a respective connection count below an underuse threshold;
selecting, by the first base station that is overloaded, based at least in part on the second base station having a respective connection count below an underuse threshold, the second base station from among the plurality of base stations, wherein the second base station is located at a first position; and
instructing, by the first base station that is overloaded, the second base station to relocate from the first position to a new position closer to the first base station;
wherein the plurality of base stations automatically relocate to load-balance connections from the plurality of mobile devices.

US Pat. No. 10,368,266

EFFICIENT UPLINK SCHEDULING MECHANISMS FOR DUAL CONNECTIVITY

Sun Patent Trust, New Yo...

1. A mobile node comprising:circuitry, which, in operation,
connects to a master base station and to a secondary base station via a split bearer that is split between the master base station and the secondary base station in a Packet Data Convergence Protocol (PDCP) layer;
determines whether a total buffer occupancy of the PDCP layer in the mobile node exceeds a threshold;
responsive to the total buffer occupancy exceeding the threshold, splits the total buffer occupancy of the PDCP layer into both a first PDCP buffer occupancy value for the master base station and a second PDCP buffer occupancy value for the secondary base station;
responsive to the total buffer occupancy not exceeding the threshold, splits the total buffer occupancy of the PDCP layer based on a defined split ratio into a first PDCP buffer occupancy value for the master base station and a second PDCP buffer occupancy value for the secondary base station, wherein the defined split ratio is configured such that one of the first and second PDCP buffer occupancy values is equal to the total buffer occupancy, and the other one of the first and second PDCP buffer occupancy values is equal to zero; and
a transmitter, which is coupled to the circuitry and which, in operation, transmits a first buffer status report based on the first PDCP buffer occupancy value to the master base station responsive to the first buffer occupancy value being more than zero, and a second buffer status report based on the second PDCP buffer occupancy value to the secondary base station responsive to the second buffer occupancy value being more than zero.

US Pat. No. 10,368,264

METHOD FOR TRIGGERING A BUFFER STATUS REPORTING IN DUAL CONNECTIVITY AND A DEVICE THEREFOR

LG ELECTRONICS INC., Seo...

1. A method for a user equipment (UE) operating in a wireless communication system, the UE including a processor having a packet data convergence protocol (PDCP) entity, a first Medium Access Control (MAC) entity and a second MAC entity, the method comprising:based on a first total amount of uplink data available for transmission being less than a threshold value, the first total amount based on first PDCP data:
indicating, by the PDCP entity to the first MAC entity, a volume of the first PDCP data that is available for transmission by the first MAC entity, thereby triggering transmission of a first buffer status report (BSR) by the first MAC entity; and
indicating, by the PDCP entity to the second MAC entity, that a volume of the first PDCP data that is available for transmission by the second MAC entity is ‘0’ so that no BSR is generated by the second MAC entity;
based on a second total amount of uplink data available for transmission being greater than the threshold value, the second total amount based on second PDCP data:
indicating, by the PDCP entity to the second MAC entity, a volume of the second PDCP data that is available for transmission by the second MAC entity, thereby triggering transmission of a second BSR by the second MAC entity.

US Pat. No. 10,368,263

METHOD FOR FORMING BEARER FOR PUBLIC SAFETY IN WIRELESS COMMUNICATION SYSTEM AND DEVICE THEREFOR

Samsung Electronics Co., ...

1. A bearer establishment method of a mobility management entity (MME), the method comprising:receiving a service request message for a public safety service, the service request message including information on a mission critical push to talk over long-term evolution (MCPTT) type;
determining a type of an MCPTT service based on the information on the MCPTT type; and
establishing a bearer with a priority higher than a priority of a preconfigured bearer based on the type of the MCPTT service.

US Pat. No. 10,368,262

ENHANCING QUALITY OF SERVICE FOR HIGH PRIORITY SERVICES

Apple Inc., Cupertino, C...

1. A method for operating a user equipment device (UE) communicating with a packet switched network, the method comprising:at the UE:
establishing a first bearer having first quality of service (QoS) characteristics associated with a first priority, wherein the first bearer is a dedicated IP multimedia subsystem (IMS) signaling bearer used only for IMS signaling messages, wherein the first bearer is a default IMS signaling bearer, wherein the first QoS characteristics are identified by a QoS class identifier (QCI) value of 5;
establishing a second bearer having second QoS characteristics associated with a second priority lower than the first priority, wherein the second bearer is also a dedicated IMS signaling bearer used only for IMS signaling messages, wherein the second QoS characteristics are identified by a QCI value other than 5;
using the first bearer for communication for a first set of messages having the first priority; and
using the second bearer for communication for a second set of messages having the second priority.

US Pat. No. 10,368,261

SYNCHRONIZATION METHOD AND APPARATUS FOR D2D COMMUNICATION

Samsung Electronics Co., ...

1. A device-to-device (D2D) communication method in a user equipment (UE), the method comprising:receiving, from a network entity, configuration information comprising information of a first threshold;
acquiring information of a second threshold;
if the UE is in a network coverage for D2D communication, measuring a reception power of a first synchronization signal received from a base station, the first synchronization signal comprising a reference signal for D2D communication;
if the reception power of the first synchronization signal received from the base station is less than the first threshold, determining that the UE operates as a new synchronization reference UE to transmit a synchronization signal for D2D communication and D2D resource configuration information indicating a D2D resource region;
if the UE is out of the network coverage for D2D communication, measuring a reception power of a second synchronization signal received from another synchronization reference UE; and
if the reception power of the second synchronization signal received from the other synchronization reference UE is less than the second threshold, determining that the UE operates as the new synchronization reference UE to transmit the synchronization signal for D2D communication and D2D resource configuration information indicating a D2D resource region.

US Pat. No. 10,368,260

METHOD AND UE FOR MEASURING CSI-RS

Samsung Electronics Co., ...

1. A method to measure a channel state indication (CSI)-reference signal (RS) in a user equipment (UE), the method comprising:receiving a signal including configuration information and combination information, the combination information indicating a combination of at least two CSI-RS resources selected from among a plurality of CSI-RS resources;
obtaining a resource location based on the combination information and the configuration information; and
measuring the CSI-RS based on the resource location,
wherein the at least two CSI-RS resources indicated by the combination information are located adjacent to each other on a frequency domain, and
wherein the plurality of CSI-RS resources are represented as symbols 5 to 6 of subcarriers 2 to 4 and 7 to 9, symbols 9 to 10 of all subcarriers, and symbols 12 to 13 of subcarriers 2 to 4 and 7 to 9 , if an antenna port number is larger than 2, and the plurality of CSI-RS resources are represented as symbols 5 to 6 of subcarriers 2 to 5 and 7 to 10, symbols 9 to 10 of all subcarriers, and symbols 12 to 13 of subcarriers 2 to 5 and 7 to 10, if the antenna port number is smaller or equal to 2.

US Pat. No. 10,368,259

METHOD FOR DETERMINING SENSOR NETWORK DELAY TIME

King Fahd University of P...

1. A method of operating a computer system to determine the performance of a wireless sensor network including a plurality of sensors, the method comprising:selecting, a sensor distribution pattern for a geographical region where the sensors are to be deployed; determining a location for a base station in the geographical region;
generating by circuitry, a plurality of sensor clusters, each sensor cluster of the plurality of sensor clusters being formed by one of a first grouping mechanism and a second grouping mechanism, the first grouping mechanism forming the sensor cluster based on a strength of a signal transmitted by each sensor, that is received by the base station, and the second grouping mechanism forming the sensor cluster based on a location of the sensor and an energy level of the sensor;
allocating, for each sensor included in the generated sensor cluster, a time-slot within a time-frame corresponding to the sensor cluster, the time-slot being utilized for transmitting a data packet from the sensor to the base station; and
evaluating by the circuitry, the performance of the first grouping mechanism and the second grouping mechanism for the selected sensor distribution pattern and base station location, by computing at least a ratio of delivered data packets to the base station to a total energy consumption, and a first delay and a second delay incurred by each data packet, wherein the first delay is an average intra-cluster delay of from 0.2 to 1 second and the second delay is an average inter-cluster delay of less than 20 seconds,
wherein the selected sensor distribution pattern is a grid pattern wherein the sensors are disposed in a manner such that a distance between adjacent sensors is a predetermined distance, in a normal distribution pattern a principle number of sensors are disposed in the center of the geographical region, and in a exponential distribution pattern, a principle number of sensors are disposed in the corner of the geographical region.

US Pat. No. 10,368,258

INTERACTIONS AMONG MOBILE DEVICES IN A WIRELESS NETWORK

Empire Technology Develop...

1. A method performed under control of a first communication device to synchronize the first communication device with a second communication device, the method comprising:receiving information of the second communication device, wherein the information indicates an approximate physical distance between the first communication device and the second communication device;
determining, based on the information, a variable round-trip time for data transmission between the first communication device and the second communication device; and
synchronizing the first communication device with the second communication device based on the determined variable round-trip time, wherein synchronizing the first communication device includes inserting a dataset in data to be transmitted from the first communication device.

US Pat. No. 10,368,255

METHODS AND APPARATUS FOR CLIENT-BASED DYNAMIC CONTROL OF CONNECTIONS TO CO-EXISTING RADIO ACCESS NETWORKS

Time Warner Cable Enterpr...

1. A method for enhancing wireless connectivity for a mobile client device, the method comprising:receiving data from a first radio frequency (RF) receiver apparatus of the mobile client device;
evaluating, using a computerized process operative to run on the mobile client device, at least a portion of the received data to determine the presence of a first type of wireless signal; and
modifying, based on the determination of the presence of the first type of wireless signal, an energy detection (ED) threshold associated with a wireless interface of the mobile device, the wireless interface utilizing a second type of wireless signal, the modifying based at least in part on the data from the first RF receiver apparatus and configured to cause the mobile client device to preferentially utilize the wireless interface and the second type of wireless signal for data communications over the first type of wireless signal.

US Pat. No. 10,368,254

DATA FORWARDING METHOD AND CONTROLLER

Huawei Technologies Co., ...

1. A controller comprising:a processor; and
a memory storing instructions that when executed by the processor configure the processor for:
obtaining first identification information of a terminal, wherein the first identification information comprises terminal capability information, service type information, and quality of service QoS information of the terminal;
obtaining information about an access standard supported by a network node accessed by the terminal;
determining N functional modules in L network nodes from M network nodes according to the first identification information, wherein the N functional modules are configured to process a data stream that corresponds to a service of the terminal; and
configuring, for the L network nodes, corresponding forwarding entries for forwarding the data stream, wherein the forwarding entries are used to enable the L network nodes to process the data stream by using the N functional modules,
wherein the determining the N functional modules in the L network nodes from the M network nodes according the first identification information comprises:
determining, according to the terminal capability information of the terminal, information about an access standard supported by the terminal;
determining an access standard of the terminal according to the information about an access standard supported by the terminal and the information about an access standard supported by a network node accessed by the terminal; and
selecting the N functional modules in the L network nodes from the M network nodes according to the access standard of the terminal, the service type information, and the QoS information.

US Pat. No. 10,368,253

SYSTEM AND METHOD FOR MANAGING DUAL CONNECTIVITY WITH DYNAMIC ANCHOR CELL SELECTION

1. A system, comprising:a processing system including a processor; and
a memory that stores executable instructions that, when executed by the processing system, facilitate performance of operations, the operations comprising:
determining a plurality of dual connectivity ratings for a plurality of neighbor cells of a serving cell of a mobile cellular network, wherein the plurality of dual connectivity ratings are determined via a plurality of configuration update messages received from the plurality of neighbor cells;
identifying a dual connectivity capability of a mobile communication device that engages in wireless communications coordinated by the serving cell;
identifying a target cell of the plurality of neighbor cells based on a dual connectivity rating of the plurality of dual connectivity ratings; and
facilitating initiation of a dual connectivity service via the target cell based on the dual connectivity capability of the mobile communication device, wherein the target cell serves as a master cell of the dual connectivity service, and wherein the dual connectivity service comprises exchanging user plane messages between the mobile communication device, the master cell and a secondary cell of the mobile cellular network.

US Pat. No. 10,368,250

APPARATUS AND METHODS FOR COMMUNICATING WITH ULTRA-WIDEBAND ELECTROMAGNETIC WAVES

1. A method, comprising:generating, by a first waveguide system, a first plurality of electromagnetic waves according to a first communication signal, wherein the first plurality of electromagnetic waves conveys the first communication signal; and
guiding, by the first waveguide system, the first plurality of electromagnetic waves along a first span of a transmission medium, wherein the first span is supported by a first supporting device and a second supporting device, wherein the first waveguide system and a second waveguide system are coupled to the first span, wherein the first plurality of electromagnetic waves is directed to the second waveguide system, and wherein the first plurality of electromagnetic waves propagates along the first span of the transmission medium without requiring an electrical return path and without traversing the first supporting device or the second supporting device.

US Pat. No. 10,368,248

DYNAMIC LINK-BUDGET MONITORING AND GRAPHICAL DISPLAY

ELTA SYSTEMS LTD., Ashdo...

1. A computer-implemented method of monitoring dynamic link-budget of at least one on-board antenna fixed on a vehicle; the computer comprising at least one processor, the method comprising operating the at least one processor for:(i) calculating link-budget of the at least one on-board antenna with respect to at least one target antenna; the link-budget comprises a respective link-budget gain value assigned to each pixel in a collection of pixels, where each pixel in the collection of pixels represents a respective radiation vector in a three-dimensional space around the at least one antenna; and wherein the link-budget is calculated based on input data including gain data of the at least one antenna and navigation-data;
determining for each pixel in the collection of pixels, compliance of the respective link-budget gain value with a threshold value, thereby obtaining a respective antenna envelop of the at least one on-board antenna;
displaying on a computer display device graphical representation of a pixel map representing at least the respective antenna envelope; wherein the pixel map indicates with respect to each pixel, compliance with the threshold value, along with an indication of the relative location of the at least one target antenna;
(ii) continuously monitoring dynamics of the input data and repeating the operations in (i) wherein in each repetition:
utilizing updated navigation-data, if such exists, for updating the pixel map, and displaying on the display device an updated graphical representation of the pixel map.

US Pat. No. 10,368,246

METHODS AND SYSTEMS FOR SPECTRUM MANAGEMENT

The Research Foundation f...

1. A method for determining whether to grant a request for spectrum access, comprising:electronically receiving the request for spectrum access, wherein the request comprises a desired frequency band; a desired time period, a requested transmit power, and a requested transmitter location;
determining a geographical region based on the requested transmitter location and requested transmit power;
dividing the geographical region into a set of unit-spectrum-spaces, each unit-spectrum-space comprising a unit-region of space having a sample point, a time quanta, and a frequency band;
receiving, from an RF sensor network, current spectrum consumption information for transmitters and receivers in the geographical region;
quantifying utilized-spectrum for the geographical region by:
calculating the power received from each transmitter in the geographical region at each of a plurality of sample points, wherein each sample point of the plurality of sample points corresponds to a unit-region of the geographical region;
calculating a spectrum-occupancy for each sample point by aggregating the power received from each transmitter at the respective sample point and the average ambient noise power at the respective sample point;
calculating a spectrum-occupancy for each unit-spectrum-space within the geographical region; and
aggregating the spectrum-occupancy of each unit-spectrum-space
quantifying available-spectrum for the geographical region; and
granting or denying the request for spectrum access according to the utilized-spectrum and available-spectrum.

US Pat. No. 10,368,245

MOBILE DEVICE LOCKING

INTERNATIONAL BUSINESS MA...

1. A computer program product comprising a computer readable storage medium having program instructions embodied therewith, the program instructions executable by a mobile computer device to cause the mobile computer device to:transmit synchronization information to a remote mobile computer device;
receive synchronization response data from the remote mobile computer device based on transmitting the synchronization information;
transmit a tone to a surface of an object based on receiving the synchronization response data;
receive a compound resonance frequency from the object based on the transmitted tone;
determine the received compound resonance frequency conforms to a stored compound resonance frequency; and
unlock the mobile computer device based on the determining.

US Pat. No. 10,368,244

PROJECTION VIA A DEVICE

MICROSOFT TECHNOLOGY LICE...

1. A system comprising:one or more processors; and
one or more computer-readable media storing processor-executable instructions that, responsive to execution by the one or more processors, cause the system to perform operations including:
determining based on a current device context that a first device is permitted to broadcast its availability to receive projected content from another device;
causing discovery data that indicates that the first device is available to receive projected content to be transmitted wirelessly;
detecting a request from a second device to project a visual representation of an execution environment generated at the second device to the first device;
ascertaining whether the second device has permission to project to the first device; and
allowing or denying the second device to project the visual representation to the first device based on whether the second device is indicated as having permission to project to the first device.

US Pat. No. 10,368,243

SYSTEM AND METHOD FOR AUTHENTICATION AND SHARING OF SUBSCRIBER DATA

Sprint Communications Com...

1. A method of authenticating a wireless communication service subscriber, comprising:receiving, by a subscriber authentication server, a first request to transfer a first confidential subscriber information package associated with a first subscriber from a first wireless communication service provider to a second wireless communication service provider, where the first subscriber previously received wireless communication service from the first wireless communication service provider and has transferred service to receive wireless communication service from the second wireless communication service provider and where the second wireless communication service provider sends the first request to the subscriber authentication server, wherein the first confidential subscriber information package comprises a personal identification number (PIN) of the first subscriber and at least one answer of the first subscriber to a security question;
responsive to the first request, sending, by the subscriber authentication server, a first confidential subscriber information package transfer request to the first wireless communication service provider, wherein the first transfer request identifies the second wireless communication service provider; and
verifying, via one of the first wireless communication service provider and second wireless communication service provider, authorization by the first subscriber to transfer the first confidential subscriber information package, the verifying authorization by the first subscriber to transfer the first confidential subscriber information package comprising:
receiving, via one of the first wireless communication service provider and second wireless communication service provider, a request for authentication of the first subscriber, wherein the request for authentication of the first subscriber comprises a telephone number associated with the first subscriber and a subscriber name of the first subscriber;
verifying, via one of the first wireless communication service provider and second wireless communication service provider, correspondence between the telephone number associated with the first subscriber and the subscriber name of the first subscriber;
responsive to verifying correspondence between the telephone number associated with the first subscriber and the subscriber name of the first subscriber, transmitting, by the subscriber authentication server to a first user equipment associated with the first subscriber, a request for verification of approval to transfer the first confidential subscriber information package from the first wireless communication service provider to the second wireless communication service provider, wherein the verification of approval to transfer the first confidential subscriber information package comprises;
querying the first subscriber for personal identification information;
receiving the personal identification information entered via the first user equipment associated with the first subscriber; and
comparing the entered personal identification information to the PIN of the first subscriber, wherein authorization by the first subscriber to transfer the first confidential information package is verified based at least in part on the received personal identification information matching the PIN of the first subscriber.